{"study_id": 74719, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to evaluate the medical and surgical treatment approaches for hair restoration in women, including preoperative evaluation and postoperative management.", "results_summary": "The abstract discusses the importance of thorough preoperative evaluation, recognizing scarring alopecias, and managing postoperative hair shock loss in women undergoing hair transplant procedures. It does not specifically mention Minoxidil's effects.", "population_specificity": "Women with hair loss undergoing hair restoration treatments.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:47.361103+00:00"}
{"study_id": 74721, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to systematically review the efficacy of platelet-rich plasma (PRP) injections compared to controls for treating androgenic alopecia (AGA).", "results_summary": "The review found that 84% of studies reported a positive effect of PRP for AGA treatment, with 50% showing statistically significant improvement and 34% reporting hair density and thickness improvements, though some lacked statistical significance.", "population_specificity": "Patients with androgenic alopecia (AGA).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:47.430595+00:00"}
{"study_id": 74718, "supplement_id": 1344, "safety_score": "30", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to investigate the toxicological effects of a novel hydroxypropyl-\u03b2-cyclodextrin minoxidil gel formulation compared to a minoxidil solution, focusing on cardiovascular effects and potential cancer-related risks.", "results_summary": "The study found that repeated escalating doses of minoxidil solution caused cardiac hypertrophy, hypotension, and elevated serum natriuretic peptides. The novel gel formulation was evaluated for safety but efficacy in treating androgenetic alopecia was not clearly demonstrated.", "population_specificity": "Male rats", "effective_dosage": "0.035%-3.5% w/v (escalating doses), 3.5% w/v (single and twice daily doses)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:47.866957+00:00"}
{"study_id": 74724, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether combining finasteride and topical minoxidil is more effective and equally safe compared to monotherapy for treating androgenetic alopecia (AGA).", "results_summary": "The combined treatment showed significantly better global photographic evaluation scores and more patients with marked improvement compared to monotherapy, with no significant difference in adverse events. However, no significant differences were found in moderate/mild improvements or hair density changes.", "population_specificity": "Patients with androgenetic alopecia (AGA).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:49.070150+00:00"}
{"study_id": 74723, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to summarize the literature on oral finasteride as an alternative treatment for female pattern hair loss (FPHL) and explore novel therapeutic options, including topical finasteride and dutasteride.", "results_summary": "The abstract notes that topical minoxidil, the currently approved treatment for FPHL, fails to achieve hair regrowth in some patients, prompting consideration of alternatives like finasteride. However, finasteride's potential teratogenic effects limit its clinical use for FPHL.", "population_specificity": "Female patients with female pattern hair loss (FPHL).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:49.376912+00:00"}
{"study_id": 74729, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to assess the potential efficacy and safety of topical antiandrogen therapies, including minoxidil, for treating androgenetic alopecia (AGA) and acne vulgaris.", "results_summary": "The study found that topical finasteride in combination with topical minoxidil is a promising treatment for male pattern hair loss, with minimal adverse effects reported. Limited studies suggest potential efficacy for other conditions, but more research is needed.", "population_specificity": "Primarily focused on individuals with androgenetic alopecia (AGA) and acne vulgaris, with a noted need for more inclusion of women in studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:56.196204+00:00"}
{"study_id": 74731, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to determine the efficacy and safety of combining thread therapy (PLLA) with minoxidil for treating female androgenetic alopecia.", "results_summary": "The study found that combining PLLA thread therapy with minoxidil improved hair density, thickness, and appearance more effectively than minoxidil alone, with mean hair density increasing from 114 \u00b1 27 to 143 \u00b1 25/cm\u00b2.", "population_specificity": "Twenty-seven women with androgenetic alopecia.", "effective_dosage": "Not specified (minoxidil was applied bilaterally).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:56.534453+00:00"}
{"study_id": 74730, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of PRP with and without topical minoxidil against placebo and standard treatment (minoxidil alone) in improving hair regrowth in male-type baldness.", "results_summary": "The study found that PRP combined with minoxidil showed the highest improvement in hair density and patient satisfaction, followed by PRP alone, then minoxidil alone, while the normal saline group showed decreased hair density.", "population_specificity": "Males with male-type baldness.", "effective_dosage": "Not specified.", "study_duration": "3 months of intervention with 2 months of follow-up.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:56.733428+00:00"}
{"study_id": 74733, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of Minoxidil in accelerating hair regrowth as a topical therapy for alopecia caused by oncological treatments.", "results_summary": "The study found that Minoxidil accelerates hair regrowth and is used as a topical therapy for alopecia, though its effectiveness and availability are limited compared to other methods like scalp cooling.", "population_specificity": "Patients with alopecia caused by chemotherapy, radiotherapy, or targeted and hormonal therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:57.264252+00:00"}
{"study_id": 74725, "supplement_id": 1344, "safety_score": "83", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of topical 5% minoxidil gel versus 0.2% GTN cream in treating chronic anal fissures.", "results_summary": "Topical 5% minoxidil gel achieved higher healing rates (76.7% vs. 46.9%) and faster healing (4.1 vs. 5.3 weeks) compared to GTN, with fewer adverse effects (6.6% vs. 40.6%). However, GTN provided significantly lower post-treatment pain scores than minoxidil.", "population_specificity": "Adult patients with chronic anal fissures (36 female, 26 male).", "effective_dosage": "5% minoxidil gel (frequency not specified).", "study_duration": "Average healing time was 4.1 weeks for minoxidil.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:57.388065+00:00"}
{"study_id": 74728, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy of topical ketoconazole as an alternative or adjunctive treatment for androgenetic alopecia (AGA) in patients who do not adequately respond to first-line treatments like finasteride or minoxidil.", "results_summary": "The study found that topical ketoconazole showed promise in treating AGA, with murine studies indicating significant hair regrowth and human studies reporting increased hair shaft diameter and clinical improvement based on photographic and subjective assessments.", "population_specificity": "The study included two animal studies (40 participants) and five human studies (318 participants) focusing on individuals with androgenetic alopecia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:57.603022+00:00"}
{"study_id": 74732, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to provide an update on Female Androgenetic Alopecia (FAGA) and establish guidelines for its diagnosis and management, including the role of topical minoxidil.", "results_summary": "The abstract highlights that topical minoxidil is one of the most important drugs for treating FAGA, aiming to stop disease progression and induce cosmetically acceptable hair regrowth. However, specific efficacy data or comparative outcomes are not detailed.", "population_specificity": "Women with Female Androgenetic Alopecia (FAGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:58.070182+00:00"}
{"study_id": 74727, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of combined oral finasteride and topical minoxidil (2% or 5%) on hair cycling and growth in male-pattern hair loss.", "results_summary": "Combined treatment with oral finasteride and topical minoxidil 5% improved hair growth (compound index increased from 30% to 60%), but the effect was not sustained by finasteride alone. No significant transformation of miniaturized follicles into terminal hair-producing follicles was observed.", "population_specificity": "Male volunteers with male-pattern hair loss (n=22 initially, n=14 in dose-effect study).", "effective_dosage": "Topical minoxidil 2% or 5% (1 mL/day).", "study_duration": "12 months for oral finasteride, followed by 3-month \"on-lotion\" and 3-month \"off-lotion\" cycles for topical minoxidil.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:43:59.006283+00:00"}
{"study_id": 74734, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness of PRP and topical minoxidil in treating androgenic alopecia in women.", "results_summary": "Minoxidil significantly increased hair count, vellus hair density, terminal hair density, and cumulative thickness, outperforming PRP in hair regrowth metrics. However, PRP improved quality of life responses, whereas minoxidil did not.", "population_specificity": "Twenty women with androgenic alopecia.", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:03.990967+00:00"}
{"study_id": 74737, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of various hair loss treatments, including Minoxidil, in terms of patient satisfaction.", "results_summary": "The study included four articles on Minoxidil, but specific efficacy results were not detailed in the abstract. The review focused on comparing multiple treatments, with Minoxidil being one of several options assessed.", "population_specificity": "Patients seeking treatment for hair loss (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:04.089452+00:00"}
{"study_id": 74735, "supplement_id": 1344, "safety_score": "75", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to review and update current information on the pharmacology, mechanism of action, clinical efficacy, and adverse events of topical minoxidil.", "results_summary": "Topical minoxidil is the mainstay treatment for androgenetic alopecia and is used off-label for other hair loss conditions, though its exact mechanism of action remains unclear. The study highlights its widespread application and reviews its efficacy and adverse events.", "population_specificity": "Not specified (general review, not a specific study population).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:04.560620+00:00"}
{"study_id": 74741, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review herbal and fungal medicines used in androgenic alopecia, including their mechanisms and active constituents, but did not specifically focus on evaluating Minoxidil.", "results_summary": "The abstract does not provide specific findings about Minoxidil's effects, as the study primarily reviewed herbal and fungal treatments for androgenic alopecia.", "population_specificity": "Not specified (general focus on androgenic alopecia patients).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:05.639066+00:00"}
{"study_id": 74738, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to review existing literature on androgenetic alopecia (AGA) in pediatric/adolescent populations, including the use of topical minoxidil.", "results_summary": "The study found that topical minoxidil, though not approved for pediatric use, has been used successfully in treating AGA in children and adolescents. Other treatments for AGA in this population are poorly studied.", "population_specificity": "Pediatric and adolescent patients (under 18 years) with androgenetic alopecia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:06.016680+00:00"}
{"study_id": 74739, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of 5% and 10% topical minoxidil versus placebo in treating androgenetic alopecia (AGA) in men.", "results_summary": "The study found that 5% minoxidil was significantly superior to 10% minoxidil and placebo in increasing hair regrowth, with no reported sexual dysfunction. However, 10% minoxidil caused marked irritation and worsened psychosocial stress due to shedding and high expectations.", "population_specificity": "90 men with androgenetic alopecia.", "effective_dosage": "5% and 10% topical minoxidil solutions applied as per study protocol.", "study_duration": "36 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:06.518781+00:00"}
{"study_id": 74742, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the regenerative medicine aspects of alopecia areata (AA) and vitiligo, including the potential benefits of minoxidil in AA.", "results_summary": "The study found that minoxidil showed some benefit in AA, alongside other treatments like JAK inhibitors and platelet-rich plasma, but did not provide detailed efficacy data or comparative analysis.", "population_specificity": "Patients with alopecia areata (AA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:06.650356+00:00"}
{"study_id": 74740, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the effectiveness of a 1,540 nm fractional erbium-glass laser combined with topical minoxidil solution in treating alopecia areata (AA) compared to minoxidil alone.", "results_summary": "The study found that patches treated with laser therapy and minoxidil showed a 30% hair increment and a 60% response rate, compared to 6.45% and 16% for minoxidil alone, indicating enhanced efficacy with combined treatment.", "population_specificity": "Patients with alopecia areata (AA) patches.", "effective_dosage": "Topical minoxidil solution applied twice daily.", "study_duration": "6 weeks of treatment followed by 6 weeks of follow-up.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:07.062641+00:00"}
{"study_id": 74745, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to characterize the effects of age-related hair changes on age perception and attractiveness, highlighting the importance of addressing hair loss in anti-aging consultations.", "results_summary": "The study found that hair density peaks around age 27 and declines thereafter, emphasizing the need for holistic anti-aging strategies that include hair preservation to complement facial rejuvenation efforts.", "population_specificity": "General population with focus on intrinsic and extrinsic hair aging.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:12.204094+00:00"}
{"study_id": 74744, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to compare the initial efficacy and safety of mesotherapy containing nutritional supplements to topical minoxidil 5% solution in treating female pattern hair loss (FPHL).", "results_summary": "The study found no significant difference in hair density, hair loss, or Ludwig's classification improvement between minoxidil and mesotherapy groups. However, mesotherapy showed a significant increase in hair follicle count and higher patient satisfaction compared to minoxidil.", "population_specificity": "30 female patients with FPHL.", "effective_dosage": "Minoxidil 5% lotion applied twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:12.810897+00:00"}
{"study_id": 74747, "supplement_id": 1344, "safety_score": "60", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to review conventional drugs like minoxidil for treating androgenetic alopecia (AGA) and compare them with potential herbal alternatives.", "results_summary": "The abstract mentions that minoxidil is widely used for AGA treatment but highlights drawbacks such as allergic contact dermatitis and burning. It suggests herbal alternatives may offer similar efficacy with fewer side effects.", "population_specificity": "Individuals with androgenetic alopecia (both sexes, though males experience more significant hair loss).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:14.054535+00:00"}
{"study_id": 74746, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of fractional Er:Glass laser therapy combined with topical 5% minoxidil versus 5% minoxidil alone for treating male androgenetic alopecia.", "results_summary": "Combination therapy (laser + minoxidil) showed significantly superior results in hair density, diameter, and global photographic assessment compared to minoxidil alone, with no serious adverse events reported.", "population_specificity": "30 men with androgenetic alopecia (29 completed the study).", "effective_dosage": "Topical 5% minoxidil (frequency not specified).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:15.780574+00:00"}
{"study_id": 74749, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness and safety of minoxidil as an intervention for patchy alopecia areata in children and adults.", "results_summary": "The meta-analysis showed a significant difference favoring 5% minoxidil over placebo, with moderate-quality evidence supporting its effectiveness and no severe adverse events reported. The treatment was deemed clinically and statistically safe, though further studies with larger samples and longer durations are needed.", "population_specificity": "Children and adults with patchy alopecia areata.", "effective_dosage": "5% minoxidil (frequency not specified).", "study_duration": "Not specified (but outcome observations were noted to be less than 6 months).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:16.822437+00:00"}
{"study_id": 74748, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 67, "quality_score": 75, "study_goal": "The researchers aimed to assess the clinical presentation, quality of life, and treatment outcomes (including topical minoxidil) in patients with persistent chemotherapy-induced alopecia (pCIA) or endocrine therapy-induced alopecia (EIAC).", "results_summary": "Moderate to significant improvement was observed in 67% of pCIA patients and 76% of EIAC patients treated with topical minoxidil or spironolactone, indicating modest efficacy. Both groups reported negative emotional effects from alopecia.", "population_specificity": "192 women with cancer (98 with pCIA, 94 with EIAC) treated with cytotoxic agents or endocrine therapy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:17.086588+00:00"}
{"study_id": 74750, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the clinical efficacy of topical minoxidil for treating various types of hair loss, including androgenetic alopecia, alopecia areata, traction alopecia, and congenital hair disorders.", "results_summary": "Topical minoxidil demonstrated efficacy in treating hair loss, with hair growth improvements ranging from 17% to 70% depending on concentration and condition. Combination therapies with minoxidil showed increased effectiveness over monotherapies.", "population_specificity": "Human subjects with various types of hair loss, including male and female androgenetic alopecia, alopecia areata, traction alopecia, and congenital hair disorders.", "effective_dosage": "Concentrations ranged from 0.01% to 15%, with specific uses of 3%-5% for alopecia areata, 2% for traction alopecia, and 1%-5% for congenital hair disorders.", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:18.109253+00:00"}
{"study_id": 74751, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to provide evidence-based recommendations for treating female pattern hair loss (FPHL), including the use of minoxidil.", "results_summary": "The study recommends minoxidil (5%) as the first-line treatment for FPHL, with additional therapies like 5\u03b1-reductase inhibitors or antiandrogens for severe cases or hyperandrogenism.", "population_specificity": "Women with female pattern hair loss (FPHL).", "effective_dosage": "5% minoxidil (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:20.410907+00:00"}
{"study_id": 74752, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to explore the use of minoxidil as a treatment option for frontal fibrosing alopecia (FFA), a chronic condition with no validated or approved therapy.", "results_summary": "The abstract mentions minoxidil as a commonly prescribed topical treatment for FFA but does not provide specific efficacy data or outcomes related to its use in this condition.", "population_specificity": "Patients with frontal fibrosing alopecia (FFA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:20.817034+00:00"}
{"study_id": 74753, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to review emerging treatments for androgenetic alopecia and alopecia areata, comparing their efficacy to topical minoxidil.", "results_summary": "The study found that while JAK inhibitors show promise for alopecia areata, topical minoxidil remains a benchmark for androgenetic alopecia, though researchers are seeking superior alternatives. Stem-cell research may offer future solutions for hair follicle regeneration.", "population_specificity": "Patients with androgenetic alopecia and alopecia areata.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:22.375460+00:00"}
{"study_id": 74743, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy and safety of minoxidil on Intima Media Thickness (IMT) in patients with Williams-Beuren syndrome over a 12-month treatment period.", "results_summary": "The study found a slight increase in IMT after 12 and 18 months in the minoxidil group compared to placebo, with no significant difference at 12 months but a statistically significant increase at 18 months. Two serious adverse events occurred, but they were unrelated to the treatment.", "population_specificity": "Children with Williams-Beuren syndrome.", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:22.651800+00:00"}
{"study_id": 74756, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to summarize safety concerns associated with novel therapeutic modalities, including oral minoxidil, for treating hair loss.", "results_summary": "The abstract indicates that emerging treatments like oral minoxidil demonstrate efficacy in hair regrowth but have varying safety profiles. No specific adverse effects or efficacy data for minoxidil are detailed.", "population_specificity": "Patients with non-scarring alopecias (generalized, not further specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:24.993838+00:00"}
{"study_id": 74755, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 60, "study_goal": "The researchers aimed to outline a treatment algorithm for alopecia areata, including the role of topical therapies like minoxidil in limited disease cases.", "results_summary": "The abstract mentions minoxidil as a topical therapy option for limited alopecia areata but does not provide specific efficacy data or outcomes for minoxidil alone. It highlights the lack of comprehensive data on effectiveness and tolerability for various treatments, including minoxidil.", "population_specificity": "Individuals with alopecia areata, particularly those with limited disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:25.294976+00:00"}
{"study_id": 74754, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to review the evidence for the efficacy and safety of topical minoxidil in treating various types of alopecia, including its off-label uses.", "results_summary": "The study found mixed evidence for minoxidil's efficacy, with stronger support for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia, but inconclusive results for alopecia areata and scarring alopecias. Minoxidil's safety profile is well-established in adults but may require closer monitoring in pediatric use.", "population_specificity": "Adults and pediatric patients with various types of alopecia (androgenetic alopecia, telogen effluvium, alopecia areata, scarring alopecia, eyebrow hypotrichosis, monilethrix, and chemotherapy-induced alopecia).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:25.681875+00:00"}
{"study_id": 74757, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to compare the efficacy of pentoxifylline (PTX) and triamcinolone acetonide (TRA) intralesional injections for treating localized alopecia areata, not to evaluate Minoxidil.", "results_summary": "The study did not investigate Minoxidil; it focused on PTX and TRA, finding combined PTX and TRA most effective (72.0% response), followed by PTX alone (60.0%) and TRA alone (32.0%).", "population_specificity": "75 patients (47 males, 28 females) aged 18-55 with localized alopecia areata.", "effective_dosage": "Not mentioned for Minoxidil.", "study_duration": "Not mentioned for Minoxidil.", "interactions": "None mentioned for Minoxidil.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:28.442935+00:00"}
{"study_id": 74759, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to compare the safety, efficacy, and compliance of topical minoxidil and oral finasteride for treating male androgenetic alopecia (AGA).", "results_summary": "Topical minoxidil has a well-established safety record but shows limited efficacy, with less than 40% of men responding after 24 weeks of treatment. Compliance is low due to its topical administration.", "population_specificity": "Men with androgenetic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:29.107547+00:00"}
{"study_id": 74760, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of topical 0.25% finasteride combined with 3% minoxidil versus 3% minoxidil monotherapy in treating female pattern hair loss (FPHL).", "results_summary": "Both treatments increased hair density and diameter, but the finasteride/minoxidil combination was significantly superior in improving hair diameter. No systemic side effects were reported, though serum dihydrotestosterone levels decreased in the combination group.", "population_specificity": "30 postmenopausal women with FPHL.", "effective_dosage": "3% minoxidil solution (frequency not specified).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:30.772754+00:00"}
{"study_id": 74761, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize findings from pivotal studies supporting Minoxidil's approval and review recent developments in its use for treating androgenetic alopecia (AGA).", "results_summary": "Minoxidil is the only topical drug approved for treating both male and female pattern hair loss, with OTC availability in the US at a maximum concentration of 5%. The abstract highlights its pivotal studies and novel developments but does not detail specific efficacy outcomes.", "population_specificity": "Men and women with androgenetic alopecia (AGA).", "effective_dosage": "Maximum concentration of 5% (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:31.129036+00:00"}
{"study_id": 74762, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy and safety of a topical solution combining 0.25% finasteride with 3% minoxidil versus 3% minoxidil alone in treating androgenetic alopecia in men.", "results_summary": "The combined finasteride-minoxidil solution significantly outperformed minoxidil alone in improving hair density, hair diameter, and global photographic assessment, with 90% of patients experiencing moderate to marked improvement. The solution had minimal impact on plasma dihydrotestosterone levels (5% reduction) and no systemic adverse events were reported.", "population_specificity": "Men aged 18-60 years with androgenetic alopecia.", "effective_dosage": "3% minoxidil solution applied twice daily (combined with 0.25% finasteride in the experimental group).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:32.740206+00:00"}
{"study_id": 74765, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether a new minoxidil formulation (DC0120) was noninferior to a marketed comparator (ALOSTIL) in treating androgenetic alopecia (AGA) in men.", "results_summary": "The study found that DC0120 was as effective as the comparator, with a mean increase of +22.0 hairs/cm\u00b2 at week 16, and demonstrated similar safety.", "population_specificity": "Men with androgenetic alopecia (AGA).", "effective_dosage": "Not specified in the abstract.", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:33.876855+00:00"}
{"study_id": 74763, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 90, "quality_score": 75, "study_goal": "To evaluate the efficacy and safety of combined fractional radiofrequency microneedling (FRM) and 5% topical minoxidil in the treatment of male pattern hair loss.", "results_summary": "Combined treatment with FRM and 5% topical minoxidil showed significantly greater improvements in hair count and thickness compared to minoxidil monotherapy, with statistical significance (P = 0.01 for hair count, P = 0.02 for hair thickness). The treatment was deemed effective and safe.", "population_specificity": "19 Chinese men with male pattern hair loss.", "effective_dosage": "5% topical minoxidil applied twice daily.", "study_duration": "5 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:34.399006+00:00"}
{"study_id": 74764, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to update guidelines for treating male-pattern and female-pattern hair loss, evaluating the safety and efficacy of minoxidil among other treatments.", "results_summary": "The study recommends topical 5% minoxidil twice daily for MPHL and 1% minoxidil twice daily for FPHL as first-line treatments, indicating its effectiveness, while noting oral administration of minoxidil should not be performed.", "population_specificity": "Patients with male-pattern hair loss (MPHL) and female-pattern hair loss (FPHL).", "effective_dosage": "5% minoxidil twice daily for MPHL, 1% minoxidil twice daily for FPHL.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:34.598719+00:00"}
{"study_id": 74767, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to elucidate the mechanism of action of minoxidil and confirm its efficacy in treating androgenetic alopecia.", "results_summary": "Minoxidil shortens telogen, accelerates the telogen-exogen phase, and promotes premature entry of hair follicles into the anagen phase, increasing hair follicle size. It significantly increases non-vellus hair count from baseline.", "population_specificity": "Humans with androgenetic alopecia.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:36.877648+00:00"}
{"study_id": 74766, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of topical finasteride as an alternative treatment for androgenetic alopecia, comparing it to systemic finasteride and minoxidil.", "results_summary": "Topical finasteride significantly reduced hair loss, increased total and terminal hair counts, and improved hair growth assessments. It also decreased scalp and plasma DHT without affecting serum testosterone levels.", "population_specificity": "Patients with androgenetic alopecia.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:37.024293+00:00"}
{"study_id": 74769, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specifically address Minoxidil; it broadly evaluates therapies for alopecia areata, including new treatments like Janus kinase inhibitors.", "results_summary": "The abstract does not provide specific findings on Minoxidil; it discusses variable clinical outcomes of available therapies and evaluates new treatments.", "population_specificity": "Not specified (general discussion of pediatric vs. adult populations and disease severity).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:39.700362+00:00"}
{"study_id": 74768, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and adverse effects of topically applied minoxidil compared to diltiazem for treating chronic anal fissures.", "results_summary": "Minoxidil was equally effective as diltiazem in reducing pain, bleeding, and improving fissure healing, with no significant differences in adverse effects except for slightly higher itching in the minoxidil group initially. Allergy occurred in two minoxidil patients but was not severe.", "population_specificity": "88 patients aged 15-65 years with chronic anal fissures.", "effective_dosage": "0.5% minoxidil cream applied twice daily.", "study_duration": "2 weeks of treatment, with follow-up assessments for 2 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:39.829745+00:00"}
{"study_id": 74771, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of minoxidil in treating resistant or uncontrolled hypertension.", "results_summary": "The study found that minoxidil is particularly effective in a subgroup of patients with treatment-resistant or uncontrolled hypertension, highlighting its potential as a pharmacological approach.", "population_specificity": "Patients with resistant or uncontrolled hypertension, particularly those with older age, obesity, diabetes, sleep apnea, or chronic kidney disease.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:41.506266+00:00"}
{"study_id": 74770, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety and efficacy of once-daily oral minoxidil 0.25 mg combined with spironolactone 25 mg in treating female pattern hair loss (FPHL).", "results_summary": "The study found that the treatment reduced hair loss severity and shedding scores over 12 months, with mild side effects reported in only eight women. Blood pressure decreased slightly, and no significant adverse effects or blood test abnormalities were observed.", "population_specificity": "Women aged 18-80 with Sinclair stage 2-5 pattern hair loss (PHL).", "effective_dosage": "Minoxidil 0.25 mg and spironolactone 25 mg once daily.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:42.088949+00:00"}
{"study_id": 74773, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether JetPeel-assisted topical minoxidil is more effective than minoxidil monotherapy in treating androgenetic alopecia (AGA).", "results_summary": "The study found that JetPeel-assisted topical minoxidil resulted in significantly greater hair growth improvement compared to minoxidil monotherapy and no treatment, with statistically significant results (p < 0.05).", "population_specificity": "Thirty patients with androgenetic alopecia, randomly divided into three groups.", "effective_dosage": "Not specified", "study_duration": "Every other month (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:42.733583+00:00"}
{"study_id": 74772, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of microneedling, particularly in combination with minoxidil, to improve hair growth in conditions like androgenetic alopecia.", "results_summary": "The study found that microneedling, when paired with minoxidil, can stimulate hair follicle growth, likely by enhancing the penetration of minoxidil. However, the evidence does not conclusively prove microneedling's superiority over standard therapies.", "population_specificity": "Patients with androgenetic alopecia and alopecia areata.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:42.907061+00:00"}
{"study_id": 74776, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to evaluate the effectiveness of fractional lasers for hair regrowth, comparing them to existing treatments like minoxidil.", "results_summary": "The abstract does not provide specific findings about minoxidil's effects, focusing instead on fractional laser therapies for hair loss.", "population_specificity": "Not specified for minoxidil.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:43.983832+00:00"}
{"study_id": 74774, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the benefits of a nutraceutical blend for treating hair loss as an alternative to existing treatments like minoxidil and finasteride.", "results_summary": "The abstract highlights limitations of current treatments (minoxidil and finasteride) and introduces a nutraceutical with multi-modal biologic activity targeting hair loss triggers and inflammation. Clinical studies are underway to confirm efficacy.", "population_specificity": "Patients with hair loss seeking alternative treatments.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:44.619527+00:00"}
{"study_id": 74778, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate common myths about hair loss treatments, including minoxidil, by reviewing evidence from randomized controlled trials.", "results_summary": "The study found little evidence supporting many hair loss myths but noted that some randomized controlled trials indicate the effectiveness of certain treatments like minoxidil. It emphasized the need for more rigorous trials to evaluate therapies.", "population_specificity": "Patients with hair loss (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:47.692651+00:00"}
{"study_id": 74779, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The study aimed to evaluate the efficacy of topical cetirizine versus placebo in patients with androgenetic alopecia (AGA), not Minoxidil.", "results_summary": "The study did not assess Minoxidil; it found that topical cetirizine 1% improved hair density and diameter in AGA patients.", "population_specificity": "85 patients with AGA (67 treated with cetirizine, 18 controls).", "effective_dosage": "Not mentioned (for Minoxidil).", "study_duration": "Not mentioned (for Minoxidil).", "interactions": "None mentioned (for Minoxidil).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:50.069602+00:00"}
{"study_id": 74782, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the effectiveness of minoxidil in combination with other treatments for Central Centrifugal Cicatricial Alopecia (CCCA).", "results_summary": "The study found no statistically significant difference in disease severity between subjects who received minoxidil and those who did not, suggesting minoxidil did not significantly improve outcomes in CCCA treatment.", "population_specificity": "Women of African descent with CCCA.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:50.449666+00:00"}
{"study_id": 74783, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to review the current status of dutasteride in androgenetic alopecia and compare its efficacy with finasteride, with only brief mention of minoxidil as an approved treatment.", "results_summary": "The abstract does not provide specific findings on minoxidil, only noting it as an approved treatment for androgenetic alopecia alongside finasteride, with dutasteride emerging as a potentially superior option.", "population_specificity": "Patients with androgenetic alopecia (not further specified).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:51.166144+00:00"}
{"study_id": 74781, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy and safety of topical minoxidil 5% lotion against latanoprost, betamethasone valerate, and their combination in treating patchy alopecia areata.", "results_summary": "Minoxidil 5% lotion showed statistically significant improvement in hair growth and reduction in severity scores compared to the control group, demonstrating effectiveness in treating patchy alopecia areata. The study concluded that minoxidil is both effective and safe for this condition.", "population_specificity": "Patients with patchy alopecia areata (100 participants divided into five groups of 20 each).", "effective_dosage": "5% lotion (frequency not specified).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:51.634661+00:00"}
{"study_id": 74784, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 90, "quality_score": 70, "study_goal": "The researchers aimed to evaluate minoxidil's safety, efficacy, and role in treating hypertension, particularly focusing on its potential to prevent or reverse arteriolar hypertrophy.", "results_summary": "The study found minoxidil to be highly effective in controlling blood pressure, with the author reporting personal success in maintaining optimal blood pressure (110/65-125/75) using minoxidil 5 mg/d alongside atenolol and occasional furosemide. It also suggested minoxidil may prevent or reverse arteriolar hypertrophy, a key mechanism in hypertension progression.", "population_specificity": "Extremely severely hypertensive patients with measurable nephrosclerotic kidney damage, and the author's personal case (84-year-old with a history of hypertension and stroke).", "effective_dosage": "5 mg/d", "study_duration": "Not specified", "interactions": "Used with atenolol and occasional furosemide; dietary salt restriction noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:53.823531+00:00"}
{"study_id": 74785, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether increasing the dosage of topical minoxidil to 15% would improve hair regrowth in female pattern hair loss (FPHL) patients who did not respond to 5% minoxidil, without increasing adverse events.", "results_summary": "At 12 weeks, 60% of subjects achieved clinically significant hair regrowth, with no significant hemodynamic changes or adverse events reported. The study suggests higher-dose minoxidil may benefit non-responders to standard treatment.", "population_specificity": "Female pattern hair loss (FPHL) patients identified as non-responders to 5% topical minoxidil.", "effective_dosage": "15% topical minoxidil solution (frequency not specified).", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:53.987497+00:00"}
{"study_id": 74787, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 30, "study_goal": "The researchers reviewed treatments for alopecia areata, including Minoxidil, to assess its role in managing the condition.", "results_summary": "The abstract mentions Minoxidil as one of several medications used for alopecia areata but does not provide specific findings on its effectiveness. The variability of disease extension influences treatment choice.", "population_specificity": "Patients with alopecia areata (no further specifics provided).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:57.111108+00:00"}
{"study_id": 74786, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 80, "quality_score": 65, "study_goal": "The researchers aimed to compare the efficacy and safety of 5% minoxidil solution with 5% minoxidil milky lotion in treating male androgenetic alopecia (AGA).", "results_summary": "The 5% minoxidil milky lotion showed a significantly higher increase in hair density at 8 weeks compared to the solution (37.4% vs. 8.8%), but no significant difference was observed at 16 and 24 weeks. Both formulations were found to be safe, with only mild irritation reported in one case for the milky lotion.", "population_specificity": "Twenty males with AGA, aged 26-65 years.", "effective_dosage": "5% minoxidil solution or 5% minoxidil milky lotion (frequency not specified).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:44:57.703009+00:00"}
{"study_id": 74788, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to compare the efficacy of topical minoxidil 5% versus platelet-rich plasma (PRP) in treating alopecia areata, using clinical and trichoscopic evaluation.", "results_summary": "Minoxidil 5% showed significant hair growth compared to placebo, though PRP demonstrated earlier and more effective regrowth, reduction in vellus hair, and dystrophic hair. Both treatments outperformed placebo (p < .05).", "population_specificity": "90 patients with alopecia areata, divided into three groups (minoxidil, PRP, placebo).", "effective_dosage": "Topical minoxidil 5% solution (frequency not specified).", "study_duration": "3 months, with monthly follow-ups.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:00.027055+00:00"}
{"study_id": 74789, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the role of Minoxidil in treating alopecia areata, particularly its efficacy and potential as part of combination therapy.", "results_summary": "Minoxidil was suggested as a potential treatment for alopecia areata, often in combination with other therapies, but the abstract does not provide specific efficacy data or outcomes. Ongoing research indicates promising new directions, but Minoxidil's standalone effectiveness remains unclear.", "population_specificity": "Patients with alopecia areata, ranging from mild to severe cases.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:00.221937+00:00"}
{"study_id": 74790, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine how minoxidil and human platelet lysate (HPL) influence gene expression in hair follicle bulge and dermal papilla (DP) cells to promote hair growth.", "results_summary": "Minoxidil improved bulge and DP cell survival and altered mRNA levels of Kras, Akt, Erk, Shh, and \u03b2-catenin, suggesting activation of hair growth pathways. HPL reduced apoptosis in DP cells and upregulated Erk and \u03b2-catenin in bulge cells, but had less impact on Kras and Akt.", "population_specificity": "Mouse hair follicle cells (bulge and dermal papilla regions).", "effective_dosage": "100\u03bcM minoxidil.", "study_duration": "10 days of treatment after 14 days of culture.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:00.873225+00:00"}
{"study_id": 74791, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the efficacy and safety of minoxidil 5% topical foam in treating male pattern hair loss and assess patient satisfaction.", "results_summary": "The study found significant increases in hair counts at 16 and 24 weeks compared to baseline, indicating minoxidil 5% topical foam is effective for male pattern hair loss. No major safety concerns were reported.", "population_specificity": "17 male patients with male pattern hair loss (14 completed 16 weeks, 12 completed 24 weeks).", "effective_dosage": "1 ml (one capful) of minoxidil 5% topical foam applied daily.", "study_duration": "6 months (24 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:02.301554+00:00"}
{"study_id": 74792, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of current treatment options, including minoxidil, for androgenetic alopecia in men and women.", "results_summary": "Minoxidil was identified as one of the therapeutic options with the highest level of evidence for treating male and female androgenetic alopecia, though specific efficacy and safety details were not provided in the abstract.", "population_specificity": "Men and women with androgenetic alopecia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:02.615968+00:00"}
{"study_id": 74793, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 50, "study_goal": "The researchers aimed to describe the clinical characteristics of frontal fibrosing alopecia (FFA) in men and compare them to existing literature, including the use of minoxidil as a treatment.", "results_summary": "Minoxidil was prescribed to 33% of the men in the study, but the abstract does not detail its efficacy or outcomes. The study primarily focused on clinical characteristics rather than treatment effectiveness.", "population_specificity": "Twelve men (mean age 75 years) with frontal fibrosing alopecia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:04.739154+00:00"}
{"study_id": 74794, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of minoxidil in treating androgenetic alopecia (AGA) and its effectiveness as an approved therapeutic option.", "results_summary": "The study highlights that minoxidil is one of only two FDA and EMA-approved treatments for AGA, emphasizing its efficacy in promoting hair growth when used continuously. It also notes the importance of personalized therapy targeting different pathophysiological aspects of AGA.", "population_specificity": "Men with androgenetic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Indefinite (treatment should be continued indefinitely for maintained benefit).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:06.496914+00:00"}
{"study_id": 74777, "supplement_id": 1344, "safety_score": "75", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether lecithin-based microparticles in minoxidil solution enhance topical delivery, improve hair growth, and reduce skin irritation compared to commercial minoxidil solution.", "results_summary": "Minoxidil with lecithin microparticles showed higher skin penetration and retention, equivalent hair regrowth to commercial minoxidil, and significantly reduced skin irritation compared to the commercial product, which caused crust formation.", "population_specificity": "C57BL/6 mice", "effective_dosage": "5% minoxidil solution", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:07.331243+00:00"}
{"study_id": 74796, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 90, "quality_score": 95, "study_goal": "To compare the efficacy and safety of once-daily 5% minoxidil topical foam (MTF) with vehicle foam for the treatment of female pattern hair loss (FPHL).", "results_summary": "At 12 and 24 weeks, 5% MTF treatment resulted in significant hair regrowth (10.9 hairs/cm\u00b2 at 12 weeks and 20.9 hairs/cm\u00b2 at 24 weeks) and improved scalp coverage compared to vehicle foam. The treatment was well tolerated and increased hair density.", "population_specificity": "Women aged at least 18 years with FPHL (grade D3 to D6 on the Savin Density Scale).", "effective_dosage": "5% MTF once daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:09.111965+00:00"}
{"study_id": 74797, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to review the literature on the prognosis and treatment options for hair shaft disorders, including the effectiveness of minoxidil.", "results_summary": "The study found that minoxidil improves certain hair shaft disorders such as trichorrhexis nodosa, monilethrix, pili annulati, and pili bifurcati. However, findings were limited to case reports and small case series, with no large-scale studies identified.", "population_specificity": "Individuals with hair shaft disorders (e.g., trichorrhexis nodosa, monilethrix, pili annulati, pili bifurcati).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:09.414663+00:00"}
{"study_id": 74795, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether once-daily 5% minoxidil topical foam (MTF) was noninferior to twice-daily 2% minoxidil topical solution (MTS) in treating female pattern hair loss, based on changes in target area hair count (TAHC).", "results_summary": "Once-daily 5% MTF increased TAHC by 23.9 hairs/cm\u00b2 at 24 weeks, while twice-daily 2% MTS increased it by 22.2 hairs/cm\u00b2. However, the prespecified noninferiority criteria were not met, though both treatments induced hair regrowth.", "population_specificity": "Women with female pattern hair loss (n=161 per group).", "effective_dosage": "5% MTF once daily or 2% MTS twice daily.", "study_duration": "52 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:09.535498+00:00"}
{"study_id": 74799, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a twice-daily regimen of 5% minoxidil foam combined with a novel botanical hair solution in treating mild to moderate androgenic alopecia.", "results_summary": "The study found significant improvement in scalp hair coverage and perception of overall treatment benefit as early as 4 weeks, with high subject satisfaction and tolerability. Both investigator and subject ratings indicated improved hair growth and appearance.", "population_specificity": "56 subjects with mild to moderate androgenic alopecia.", "effective_dosage": "5% minoxidil foam applied twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:10.562825+00:00"}
{"study_id": 74798, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 50, "study_goal": "The researchers aimed to review the literature on the prognosis and treatment options for hair shaft disorders, including the effectiveness of minoxidil.", "results_summary": "The study found that minoxidil improved certain hair shaft disorders such as trichorrhexis nodosa, monilethrix, pili annulati, and pili bifurcati, but no specific treatment exists for congenital hair shaft abnormalities.", "population_specificity": "Patients with hair shaft disorders (e.g., trichorrhexis nodosa, monilethrix, pili annulati, pili bifurcati).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:11.588162+00:00"}
{"study_id": 74800, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a twice-daily regimen of 2% minoxidil solution used in combination with a botanical hair solution over 12 weeks in subjects with female pattern hair loss (FPHL).", "results_summary": "Investigator ratings showed significant improvement in hair growth and overall treatment benefits by week 6, while subject self-ratings indicated high satisfaction with hair volume and quality improvement at week 6 and increased self-confidence and attractiveness by week 12.", "population_specificity": "54 female subjects with female pattern hair loss (FPHL).", "effective_dosage": "2% minoxidil solution applied twice daily.", "study_duration": "12 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:13.505033+00:00"}
{"study_id": 74801, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review existing treatment options for hair loss, including Minoxidil, and discuss their limitations and side effects while exploring stem cell therapy as an alternative.", "results_summary": "The abstract mentions Minoxidil as a current treatment option for hair loss but highlights its disadvantages and side effects, suggesting the need for alternative therapies like stem cell-based approaches.", "population_specificity": "Not specified (general discussion of hair loss treatments)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:13.622244+00:00"}
{"study_id": 74802, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of minoxidil in treating hair loss in women, particularly in comparison to other treatments like androgen suppression or DHT blockers.", "results_summary": "The study found that minoxidil is the only drug proven to improve alopecia based on randomized controlled studies with rigorous criteria, leading the authors to incorporate it into their treatment paradigm despite concerns about hair quality.", "population_specificity": "Women with hair loss, including those with normal or increased androgen levels.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:15.528419+00:00"}
{"study_id": 74805, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of minoxidil as a first-line treatment for alopecia areata (AA) in halting hair loss or initiating regrowth.", "results_summary": "Minoxidil was identified as a first-line treatment for AA, often used alongside topical steroids, with potential to halt hair loss or promote regrowth. The abstract suggests it is safe for primary care physicians to prescribe, but efficacy in advanced or refractory cases may require additional therapies.", "population_specificity": "Both children and adults with alopecia areata.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:18.275343+00:00"}
{"study_id": 74804, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to synthesize available efficacy data on topical minoxidil for treating androgenetic alopecia (AGA) through a systematic review and meta-analysis.", "results_summary": "Minoxidil was significantly more effective than placebo in promoting total and nonvellus hair growth, with higher hair growth rates reported by both investigators and patients. However, cosmetically acceptable results were achieved in only a subset of patients, and compliance was noted as a limiting factor.", "population_specificity": "Patients with androgenetic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:18.799386+00:00"}
{"study_id": 74807, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the role of Minoxidil as an alternative antihypertensive agent, particularly in patients with renal dysfunction and refractory hypertension.", "results_summary": "The study found that Minoxidil is a useful alternative for patients with renal dysfunction and refractory hypertension, with blood pressure-lowering effects comparable to other contemporary drug classes, though large randomized trials supporting its efficacy are limited.", "population_specificity": "Patients with renal dysfunction and refractory hypertension.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:19.213302+00:00"}
{"study_id": 74806, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 50, "study_goal": "The researchers aimed to discuss available treatment options for alopecia areata, including minoxidil, and their effectiveness.", "results_summary": "The abstract mentions minoxidil as one of the treatment options for alopecia areata but does not provide specific efficacy data or outcomes related to its use.", "population_specificity": "Patients with alopecia areata (0.1-0.2% of the population).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:19.268459+00:00"}
{"study_id": 74803, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "To evaluate the long-term efficacy and safety of 5% minoxidil topical foam in treating moderate androgenetic alopecia over 104 weeks, focusing on frontotemporal and vertex areas.", "results_summary": "The study found that 5% MTF stabilized hair density, width, and scalp coverage in both frontotemporal and vertex areas over 104 weeks, with significant increases in hair width and count at certain time points, though some metrics returned to baseline by week 104. Safety and tolerability were good, with low rates of irritant contact dermatitis.", "population_specificity": "Men with androgenetic alopecia grade IIIvertex to VI.", "effective_dosage": "5% minoxidil topical foam (frequency not specified).", "study_duration": "104 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:19.462744+00:00"}
{"study_id": 74808, "supplement_id": 1344, "safety_score": "94", "efficacy_score": 59, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy and safety of finasteride, 5% topical minoxidil, and their combination in treating male androgenetic alopecia (MAGA) in Chinese individuals.", "results_summary": "At 12 months, 59% of men treated with 5% minoxidil showed improvement, which was lower than finasteride (80.5%) and combination therapy (94.1%). Adverse reactions were rare (6.1%) and resolved after discontinuation.", "population_specificity": "450 Chinese men with MAGA.", "effective_dosage": "5% topical minoxidil (frequency not specified).", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:21.885342+00:00"}
{"study_id": 74810, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the efficacy of once daily 5% minoxidil foam for treating female pattern hair loss (FPHL) and compare it to twice daily 2% minoxidil solution.", "results_summary": "The study found that 5% minoxidil foam significantly increased target area hair count compared to placebo and demonstrated noninferiority to twice daily 2% minoxidil solution. The results support the efficacy of 5% minoxidil foam as a treatment option for FPHL.", "population_specificity": "Women with female pattern hair loss (FPHL).", "effective_dosage": "5% minoxidil foam once daily and 2% minoxidil solution twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:24.111718+00:00"}
{"study_id": 74811, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "To assess the efficacy of 5% minoxidil topical foam in the frontotemporal region of male androgenetic alopecia patients compared to placebo and the vertex region after 24 weeks of treatment.", "results_summary": "5% minoxidil topical foam significantly increased hair density and width in both frontotemporal and vertex regions by week 16, with frontotemporal hair width showing a significant increase compared to placebo at 24 weeks. Users also reported significant improvements in scalp coverage for both regions.", "population_specificity": "70 males with moderate androgenetic alopecia", "effective_dosage": "5% minoxidil topical foam applied twice daily", "study_duration": "24 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:24.429862+00:00"}
{"study_id": 74813, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to review emerging treatment options and mechanisms for alopecia, including Minoxidil, but did not focus specifically on evaluating Minoxidil.", "results_summary": "The abstract does not provide specific findings about Minoxidil's effects, as it broadly discusses new therapies and mechanisms for alopecia.", "population_specificity": "Not specified (general discussion of alopecia treatments).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:25.979357+00:00"}
{"study_id": 74814, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "To determine whether scalp biopsies from men with AGA show variable gene expression before and after 8 weeks of treatment with minoxidil topical foam 5% (MTF) vs. placebo.", "results_summary": "MTF induced hair growth in both the frontal and vertex scalp of patients with AGA. It increased the expression of hair keratin-associated genes and decreased the expression of epidermal differentiation complex and inflammatory genes in both scalp regions.", "population_specificity": "16 healthy men aged 18-49 years with Hamilton-Norwood type IV-V thinning.", "effective_dosage": "Minoxidil topical foam 5%, applied twice daily.", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:27.437527+00:00"}
{"study_id": 74812, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to assess the therapeutic response of alopecia areata (AA) patients, including the use of topical 5% minoxidil lotion in combination with oral dexamethasone mini pulse therapy.", "results_summary": "The study found that 28% of patients were treated with oral dexamethasone mini pulse therapy with or without topical 5% minoxidil lotion for 12 months or more, but specific efficacy outcomes for minoxidil alone were not detailed.", "population_specificity": "290 adults (aged 18 years or above) with alopecia areata in Sri Lanka.", "effective_dosage": "Topical 5% minoxidil lotion (frequency not specified).", "study_duration": "12 months or more.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:27.857447+00:00"}
{"study_id": 74815, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of topical minoxidil as a medical treatment for androgenetic alopecia, particularly in combination with other treatments.", "results_summary": "The study found that topical minoxidil is one of the two mainstream medical treatments for androgenetic alopecia, with an additive effect when combined with oral finasteride in men. It highlights its role in achieving natural-appearing results when used alongside surgical options.", "population_specificity": "Men and women with androgenetic alopecia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:29.067823+00:00"}
{"study_id": 74817, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to assess the efficacy of topical minoxidil in preventing chemotherapy-induced alopecia (CIA) compared to controls.", "results_summary": "Topical 2% minoxidil did not significantly reduce the risk of CIA in the study. No serious adverse effects were reported for scalp cooling, but minoxidil's safety was not specifically addressed.", "population_specificity": "Breast cancer patients receiving doxorubicin- or epirubicin-containing chemotherapy.", "effective_dosage": "2% topical minoxidil (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:29.607856+00:00"}
{"study_id": 74816, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the clinical utility and validity of a sulfotransferase enzyme test in predicting patient response to topical minoxidil for androgenetic alopecia (AGA).", "results_summary": "The study confirmed that a sulfotransferase enzyme test effectively ruled out 95.9% of nonresponders to topical minoxidil for AGA. Approximately 40% of patients regrew hair after 3-6 months of treatment.", "population_specificity": "Patients with androgenetic alopecia (AGA).", "effective_dosage": "5% topical minoxidil (frequency not specified).", "study_duration": "3-6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:29.784416+00:00"}
{"study_id": 74818, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 48, "quality_score": 75, "study_goal": "The researchers aimed to review current therapeutic targets and treatments for androgenic alopecia (AGA), including the efficacy of minoxidil.", "results_summary": "The abstract states that minoxidil has a 35% success rate in treating AGA, indicating modest efficacy. It highlights the need for new drugs targeting multiple pathways for better treatment outcomes.", "population_specificity": "Individuals with androgenic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:31.842898+00:00"}
{"study_id": 74819, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to review the efficacy and safety of medical and non-medical treatments, including Minoxidil, for androgenetic alopecia (AGA) in men and women.", "results_summary": "Topical Minoxidil solution was found to be the most effective and safe treatment for female AGA and one of the best treatments for male AGA, alongside oral finasteride. The evidence quality supports its use as a primary treatment option.", "population_specificity": "Men and women with androgenetic alopecia (AGA).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:32.638560+00:00"}
{"study_id": 74820, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to replicate findings on the association between sulfotransferase activity in plucked hair follicles and minoxidil response in female patients with androgenetic alopecia (AGA).", "results_summary": "The study confirmed that sulfotransferase activity predicts treatment response with 93% sensitivity and 83% specificity, supporting the role of minoxidil sulfation in therapeutic efficacy.", "population_specificity": "Female patients with androgenetic alopecia (AGA).", "effective_dosage": "5% minoxidil solution applied daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:33.807956+00:00"}
{"study_id": 74821, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to describe the role of minoxidil in the medical treatment of androgenetic alopecia (AGA) and its diagnostic and monitoring approaches.", "results_summary": "The abstract highlights minoxidil as part of the medical treatment for AGA, alongside antiandrogen agents and 5-alpha reductase inhibitors, but does not provide specific efficacy data for minoxidil alone. AGA is described as progressive, and scalp dermoscopy is noted as a tool for monitoring treatment response.", "population_specificity": "Men and women with androgenetic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:35.720223+00:00"}
{"study_id": 74822, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine the efficacy and safety of minoxidil 2% lotion for eyebrow enhancement compared to placebo.", "results_summary": "After 16 weeks, the minoxidil group showed significantly better results in all measured outcomes (global photographic assessment, eyebrow diameter, count, and subject satisfaction) compared to placebo, with minor side effects that did not prevent study continuation.", "population_specificity": "40 patients with eyebrow hypotrichosis, randomized for minoxidil on one eyebrow and placebo on the other.", "effective_dosage": "2% minoxidil lotion (frequency not specified).", "study_duration": "16 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:36.230501+00:00"}
{"study_id": 74823, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 30, "study_goal": "The researchers aimed to review treatment options for alopecia areata, including minoxidil, and emphasize individualized approaches.", "results_summary": "The abstract mentions minoxidil as one of several treatment options for alopecia areata but does not provide specific efficacy data or comparative results. It highlights the need for customized treatment plans.", "population_specificity": "Patients with alopecia areata, varying by age, extent, and duration of scalp involvement.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:36.418339+00:00"}
{"study_id": 74825, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the clinical application of topical minoxidil and finasteride as first-line treatments for androgenetic alopecia (AGA) in primary care settings.", "results_summary": "The study found that topical minoxidil (2%-5%) applied twice daily is recommended as a first-line treatment for AGA, with the HairMax LaserComb\u00ae suggested for non-responders. The efficacy of minoxidil was supported by the reviewed studies, though specific outcomes were not detailed in the abstract.", "population_specificity": "Caucasian men with androgenetic alopecia (AGA).", "effective_dosage": "1 mL of 2%-5% topical minoxidil twice daily.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:38.755896+00:00"}
{"study_id": 74826, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review advances in managing male androgenetic alopecia, including the effectiveness of minoxidil and its combination with other treatments.", "results_summary": "The abstract notes that topical minoxidil is effective to some extent for male androgenetic alopecia, but gains are lost upon discontinuation. It also highlights the potential benefits of combining minoxidil with follicular unit grafting for long-term hair restoration.", "population_specificity": "Men with androgenetic alopecia, particularly those with early-onset hair loss (late teens or twenties).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:40.245877+00:00"}
{"study_id": 74827, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the causes of hair loss and compare the efficacy and side effects of synthetic treatments like minoxidil with alternative herbal treatments.", "results_summary": "The abstract mentions that minoxidil is commonly used for alopecia treatment but highlights its adverse effects, prompting the search for alternative herbal treatments with fewer side effects. The study does not provide specific efficacy data for minoxidil but implies it is effective yet problematic due to side effects.", "population_specificity": "Individuals with androgenetic alopecia (general population, not specified further).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:40.853425+00:00"}
{"study_id": 74828, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate Minoxidil's role as a first-line therapy for female pattern hair loss (FPHL) and its effectiveness in arresting hair loss progression.", "results_summary": "Minoxidil was found to be effective as a first-line treatment for FPHL, primarily by halting hair loss progression rather than stimulating regrowth. The study highlights its long-term use for sustained effects, with anti-androgens serving as a secondary option.", "population_specificity": "Women with female pattern hair loss (FPHL).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:41.845914+00:00"}
{"study_id": 74829, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review recent advancements in the understanding and treatment of androgenetic alopecia (AGA), including the role of minoxidil as a major treatment option.", "results_summary": "The abstract highlights minoxidil as a key treatment for AGA, alongside finasteride and hair transplantation, but does not provide specific efficacy data. It emphasizes an evidence-based approach to treatment and diagnosis.", "population_specificity": "Patients with androgenetic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:43.482517+00:00"}
{"study_id": 74830, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to compare the stability, safety, and efficacy of a multimodal microemulsion (minoxidil, diclofenac, tea tree oil) versus minoxidil alone and placebo in treating androgenic alopecia.", "results_summary": "The multimodal formulation significantly outperformed minoxidil alone and placebo in hair count, weight, and thickness, with no appreciable side effects. It also showed physical stability over 24 months.", "population_specificity": "32 men aged 18-30 years with androgenic alopecia.", "effective_dosage": "1 mL applied twice daily.", "study_duration": "32 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:45.003886+00:00"}
{"study_id": 74833, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to assess the effectiveness and safety of treatments, including varying concentrations of minoxidil, for female pattern hair loss (FPHL).", "results_summary": "Pooled data from four studies showed that minoxidil significantly increased hair regrowth compared to placebo (relative risk 1.86). Adverse events were similar between minoxidil and placebo groups, except for a reported increase with minoxidil 5% twice daily.", "population_specificity": "Women with female pattern hair loss (FPHL).", "effective_dosage": "Varying concentrations, including 5% twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:47.186226+00:00"}
{"study_id": 74831, "supplement_id": 1344, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "To compare the efficacy and safety of 3% minoxidil lotion alone versus a combined 3% minoxidil and 0.1% finasteride lotion in men with androgenetic alopecia over 24 weeks.", "results_summary": "Both treatments increased hair counts, but only the combined minoxidil-finasteride group showed statistically significant improvement. The combined treatment also demonstrated significantly greater efficacy in global photographic assessment, with no significant difference in side effects between groups.", "population_specificity": "Forty men with androgenetic alopecia.", "effective_dosage": "3% minoxidil lotion (MNX) or combined 3% minoxidil and 0.1% finasteride lotion (MFX).", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:47.519886+00:00"}
{"study_id": 74824, "supplement_id": 1344, "safety_score": "70", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of topical minoxidil 5% and adenosine 0.75% on male pattern androgenetic alopecia, focusing on recovery rates and patient satisfaction.", "results_summary": "Minoxidil showed no significant difference in recovery rates compared to adenosine after 3 and 6 months, with neither group achieving complete recovery. However, patient satisfaction was significantly higher with adenosine due to faster prevention of hair loss and appearance of new hair.", "population_specificity": "110 male patients with grade II-V Hamilton androgenetic alopecia (55 in each group, with 16 later excluded).", "effective_dosage": "Minoxidil 5% (topical application, frequency not specified).", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:47.980699+00:00"}
{"study_id": 74836, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review criteria for blood donation ineligibility, including the temporary restriction due to Minoxidil use.", "results_summary": "The study identified Minoxidil as a drug that imposes temporary ineligibility for blood donation, but did not evaluate its safety or efficacy.", "population_specificity": "Individuals undergoing hemotherapeutic procedures in Brazil.", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:49.095645+00:00"}
{"study_id": 74835, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 40, "study_goal": "The researchers were examining the effectiveness of oral finasteride as an alternative treatment for female androgenic alopecia in a patient nonresponsive to topical minoxidil.", "results_summary": "The study found that oral finasteride (1.25 mg daily) led to reduced hair shedding and increased regrowth in a patient unresponsive to minoxidil, with no reported side effects. The abstract also mentions a review of limited studies on finasteride for FAGA.", "population_specificity": "44-year-old woman with biopsy-proven female androgenic alopecia (FAGA).", "effective_dosage": "1.25 mg oral finasteride daily", "study_duration": "3.5 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:49.256982+00:00"}
{"study_id": 74834, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to systematically review randomized controlled trials on nonsurgical treatments for female pattern hair loss (FPHL), focusing on the effectiveness of topical minoxidil.", "results_summary": "Topical minoxidil (1% to 5%) was found effective in treating FPHL regardless of age or androgen levels, showing benefits in both hyperandrogenic and non-hyperandrogenic women. Antiandrogens had limited evidence of efficacy, except for oral flutamide in cases of increased serum androgens.", "population_specificity": "Women with female pattern hair loss (FPHL), including premenopausal and postmenopausal women, with or without hyperandrogenism.", "effective_dosage": "1% to 5% topical minoxidil", "study_duration": "24 to 48 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:49.784308+00:00"}
{"study_id": 74837, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review current therapeutic options for androgenetic alopecia, including minoxidil, and discuss treatments under investigation.", "results_summary": "The abstract notes minoxidil as a standard treatment for androgenetic alopecia but highlights limited clinical trial data proving its hair growth efficacy. Other treatments like dutasteride, ketoconazole, and prostaglandin analogues are also mentioned as alternatives or investigational options.", "population_specificity": "Men and women with androgenetic alopecia (up to 70% of men and 40% of women affected in their lifetime).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:51.924140+00:00"}
{"study_id": 74838, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the effectiveness and safety of minoxidil for treating female pattern hair loss in women.", "results_summary": "Minoxidil showed a significant increase in hair regrowth compared to placebo, with a 13.28 increase in total hair count per cm\u00b2. Adverse events were minimal, except for additional hair growth in non-scalp areas (5%).", "population_specificity": "Women with female pattern hair loss (androgenic alopecia).", "effective_dosage": "Minoxidil 2% twice daily and 5% once daily (mentioned for future studies).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:53.018043+00:00"}
{"study_id": 74841, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to review available antihypertensive agents, including Minoxidil, for pediatric hypertension and guide clinicians in treatment selection.", "results_summary": "The abstract does not provide specific findings on Minoxidil's effects, only noting that ACE inhibitors, ARBs, and CCAs had the strongest supporting data.", "population_specificity": "Pediatric patients with hypertension.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:54.949782+00:00"}
{"study_id": 74840, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to understand the role of minoxidil as an androgen-independent hair growth stimulator in treating female pattern hair loss (FPHL).", "results_summary": "Minoxidil was identified as an effective treatment option to arrest hair loss progression and stimulate partial hair regrowth in FPHL, particularly when initiated early. The abstract suggests it works best in combination with other treatments like androgen receptor antagonists and 5\u03b1-reductase inhibitors.", "population_specificity": "Adult Caucasian women experiencing female pattern hair loss (FPHL).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:55.594214+00:00"}
{"study_id": 74839, "supplement_id": 1344, "safety_score": "70", "efficacy_score": 80, "quality_score": 60, "study_goal": "The researchers aimed to review Minoxidil's mechanism of action, its use in dermatology, and patents related to alternative treatments for allergic reactions caused by its use.", "results_summary": "Minoxidil promotes hair growth by widening blood vessels and opening potassium channels, though its exact mechanism is unclear. It requires regular application to maintain results, with common side effects including scalp dermatitis and temporary increased hair loss due to hair cycle synchronization.", "population_specificity": "Individuals with androgenic alopecia (2% for females, 5% for males).", "effective_dosage": "2% solution for females, 5% solution for males, applied once or twice daily.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:56.424097+00:00"}
{"study_id": 74842, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the effectiveness of 2% topical minoxidil as a therapy for accelerating hair regrowth after chemotherapy-induced alopecia.", "results_summary": "The study found that 2% topical minoxidil is an effective non-camouflage option for accelerating hair regrowth after chemotherapy, though further validation from rigorous studies is needed for other proposed treatments.", "population_specificity": "Patients undergoing chemotherapy, particularly those experiencing chemotherapy-induced alopecia.", "effective_dosage": "2% topical minoxidil (frequency not specified).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:56.769694+00:00"}
{"study_id": 74844, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers did not specifically study Minoxidil; it was mentioned in the context of fluid retention with vasodilator drugs.", "results_summary": "The abstract does not report any findings specific to Minoxidil's effects.", "population_specificity": "Not specified for Minoxidil.", "effective_dosage": "Not specified for Minoxidil.", "study_duration": "Not specified for Minoxidil.", "interactions": "None mentioned for Minoxidil.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:56.957434+00:00"}
{"study_id": 74843, "supplement_id": 1344, "safety_score": "30", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the mechanisms, clinical applications, and adverse effects of minoxidil in treating hypertension.", "results_summary": "Minoxidil effectively reduces peripheral resistance by dilating arterioles but is limited to severe hypertension due to significant adverse effects, including hirsutism and cardiovascular stimulation. Its use requires careful monitoring and is often combined with other medications to mitigate side effects.", "population_specificity": "Individuals with severe hypertension unresponsive to other treatments.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Concomitant use of \u03b2-blockers and diuretics is recommended to counteract reflex tachycardia and fluid retention.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:45:57.485845+00:00"}
{"study_id": 74845, "supplement_id": 1344, "safety_score": "90", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to compare the efficacy of 5% minoxidil, 5% hexane extract of Curcuma aeruginosa, and their combination in treating androgenetic alopecia in men.", "results_summary": "The combination of 5% minoxidil and 5% Curcuma aeruginosa extract showed statistically significant improvements in hair regrowth and reduced hair shedding compared to placebo. Minoxidil alone also demonstrated some degree of hair regrowth.", "population_specificity": "87 men with androgenetic alopecia (AGA).", "effective_dosage": "5% minoxidil, applied twice daily.", "study_duration": "6 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:00.291530+00:00"}
{"study_id": 74846, "supplement_id": 1344, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to compare the efficacy, safety, and acceptability of once-daily 5% minoxidil topical foam (MTF) with twice-daily 2% minoxidil topical solution (MTS) in women with androgenetic alopecia.", "results_summary": "The study found that 5% MTF once daily was noninferior to 2% MTS twice daily in promoting hair growth, with greater but nonsignificant improvements in hair count and width. Additionally, 5% MTF was associated with fewer side effects and better aesthetic acceptability.", "population_specificity": "Women with androgenetic alopecia (n=113).", "effective_dosage": "5% MTF once daily or 2% MTS twice daily.", "study_duration": "24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:02.335172+00:00"}
{"study_id": 74847, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review treatment options for alopecia aerata (AA), including the role of minoxidil as a therapeutic choice.", "results_summary": "The abstract indicates that minoxidil is considered a treatment of choice for AA patients who actively desire intervention, alongside topical corticosteroids. Novel treatments like IL-31 antibodies and 308-nm Excimer laser were also noted as promising.", "population_specificity": "Patients with alopecia aerata, particularly those with disease onset before 20 years of age.", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:03.312188+00:00"}
{"study_id": 74848, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to review the current understanding of androgenic alopecia (AGA) and the role of FDA-approved treatments, including minoxidil, in its management.", "results_summary": "The abstract highlights minoxidil as an FDA-approved treatment for AGA but does not provide specific efficacy data. It mentions ongoing research to validate new treatments like the laser hair comb.", "population_specificity": "Men and women with androgenic alopecia (AGA).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:03.393380+00:00"}
{"study_id": 74849, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether topical minoxidil could reduce the severity or duration of chemotherapy-induced hair loss.", "results_summary": "The study found that topical minoxidil could reduce the severity or shorten the duration of chemotherapy-induced hair loss but could not prevent it entirely. No approved pharmacologic treatment currently exists for this condition.", "population_specificity": "Patients undergoing chemotherapy (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:03.578348+00:00"}
{"study_id": 74850, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 50, "study_goal": "The researchers aimed to evaluate whether topical minoxidil could reduce the severity or duration of chemotherapy-induced hair loss.", "results_summary": "Topical minoxidil reduced the severity or shortened the duration of chemotherapy-induced hair loss but did not prevent it entirely. The abstract notes that scalp cooling is the primary method to minimize hair loss, though data quality on this technique is poor.", "population_specificity": "Patients undergoing chemotherapy (specific demographics not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:04.885179+00:00"}
{"study_id": 74853, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 10, "quality_score": 80, "study_goal": "The researchers examined the efficacy of various topical treatments, including Minoxidil, for vitiligo, focusing on their use as monotherapy or in combination with other therapies.", "results_summary": "The study excluded Minoxidil from the review due to its classification as a less used or ineffective topical agent for vitiligo treatment. No positive effects or efficacy were reported for Minoxidil in this context.", "population_specificity": "Patients with vitiligo (localized or <20% skin surface area).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:05.680722+00:00"}
{"study_id": 74851, "supplement_id": 1344, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the safety and efficacy of finasteride as an alternative treatment for female alopecia in patients who do not respond to topical minoxidil.", "results_summary": "The study found that finasteride showed no benefit over placebo in controlled clinical studies for female pattern hair loss, but it may be considered for patients who fail or cannot tolerate minoxidil therapy. Hair regrowth may take 2 years or longer, and menopausal status or androgen levels do not predict response.", "population_specificity": "Women with female pattern hair loss who did not respond to topical minoxidil.", "effective_dosage": "Not specified for minoxidil (study focused on finasteride at 1 mg orally daily).", "study_duration": "Not specified for minoxidil (study suggested a 12-month trial for finasteride).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:06.922714+00:00"}
{"study_id": 26809, "supplement_id": 1345, "safety_score": "90", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to determine whether Mitoquinone mesylate (Mito-MES) is effective as a post-exposure prophylaxis treatment against SARS-CoV-2 infection in humans.", "results_summary": "Mito-MES reduced SARS-CoV-2 infection rates (30% vs. 75% in controls) and shortened symptom duration in infected participants, with no serious side effects reported.", "population_specificity": "Individuals in Los Angeles with high-grade unmasked SARS-CoV-2 exposure within 5 days prior to study entry.", "effective_dosage": "20 mg daily", "study_duration": "14 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:08.442297+00:00"}
{"study_id": 26813, "supplement_id": 1345, "safety_score": "Not Assessed", "efficacy_score": 10, "quality_score": 85, "study_goal": "The researchers aimed to determine whether long-term administration of mitoquinone mesylate could attenuate age-related oxidative damage and loss of muscle mass and function in aging skeletal muscle.", "results_summary": "Mitoquinone mesylate failed to prevent age-related muscle mass loss, improve muscle function, reduce oxidative damage, or enhance mitochondrial integrity and function in aged mice.", "population_specificity": "Wild-type C57BL/6 mice aged 24 to 28 months.", "effective_dosage": "100 \u03bcM", "study_duration": "15 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:11.202962+00:00"}
{"study_id": 26810, "supplement_id": 1345, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether Mitoquinone mesylate (MitoQ) could improve mitochondrial dysfunction in a humanized murine model of chronic HIV infection when combined with antiretroviral therapy.", "results_summary": "The study found that HIV-1-infected mice treated with antiretroviral therapy and MitoQ for 90 days showed higher ratios of mitochondrial to nuclear DNA in end organs compared to those on antiretroviral therapy alone, suggesting MitoQ may mitigate mitochondrial dysfunction in HIV.", "population_specificity": "Humanized murine model of chronic HIV infection.", "effective_dosage": "Not specified", "study_duration": "90 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:11.436894+00:00"}
{"study_id": 26812, "supplement_id": 1345, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine whether Mitoquinone mesylate (MitoQ) could prevent sepsis-induced diaphragm dysfunction by targeting mitochondrial free radical generation.", "results_summary": "MitoQ effectively preserved diaphragm force generation, mitochondrial oxygen consumption, and aconitase activity in septic mice, with delayed treatment also showing efficacy. Similar positive effects were observed in female mice and endotoxin-induced sepsis models.", "population_specificity": "Male and female mice with sepsis induced by cecal ligation puncture (CLP) or endotoxin.", "effective_dosage": "3.5 mg/kg/day intraperitoneally", "study_duration": "48 hours after surgery", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:11.933009+00:00"}
{"study_id": 26811, "supplement_id": 1345, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether MitoQuinone (MitoQ) could reduce airway inflammation, remodeling, and hyperreactivity in obese and lean mice with house dust mite-induced allergic airway disease.", "results_summary": "MitoQ reduced airway inflammation, remodeling, and hyperreactivity in both lean and obese allergic mice, and specifically decreased tissue eosinophilia in obese-allergic mice. Its effects were partly attributed to the reduction of ER stress mediated by its hydrophobic dTPP+ moiety.", "population_specificity": "Mice (lean and obese) with house dust mite-induced allergic airway disease.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:12.463553+00:00"}
{"study_id": 26377, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the therapeutic potential of molecular hydrogen, its mechanisms of action, administration methods, and advancements in treating intestinal and other diseases.", "results_summary": "The study highlights molecular hydrogen's therapeutic efficacy, its ability to permeate tissues, and its potential in treating diseases like inflammatory bowel disease, intestinal ischemia-reperfusion, and colorectal cancer. It also discusses challenges in clinical application and proposes nanoplatforms and gut microbiota interactions as solutions.", "population_specificity": "Not specified (review article covering general applications).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:13.685045+00:00"}
{"study_id": 192244, "supplement_id": 1345, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of mitochondrial-derived reactive oxygen species (mtROS) on endothelial function in middle-aged and older adults, comparing exercisers and non-exercisers.", "results_summary": "The abstract does not provide specific results regarding Mitoquinone mesylate's effects, focusing instead on the study design and participant groups.", "population_specificity": "Middle-aged and older adults (\u226545 years), divided into exercisers (n=11) and non-exercisers (n=12).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:13.979908+00:00"}
{"study_id": 26378, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 80, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the therapeutic efficacy of molecular hydrogen capsules as an adjunctive treatment for primary biliary cholangitis (PBC) in a patient with elevated liver enzymes and immune dysregulation.", "results_summary": "Molecular hydrogen capsule therapy led to significant reductions in AST and ALT levels, normalization of immune markers, decreased IgG4 levels, and improved patient-reported symptoms like fatigue and pruritus, suggesting enhanced liver function and immune regulation.", "population_specificity": "A 44-year-old male with PBC, splenomegaly, and elevated IgG4 levels presenting with acute cholestatic hepatitis.", "effective_dosage": "Not specified", "study_duration": "4 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:15.377323+00:00"}
{"study_id": 26381, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the mechanism of molecular hydrogen in alleviating oxidative stress and its potential application in periodontitis treatment.", "results_summary": "The study summarized molecular hydrogen's role as an anti-oxidative stress reagent and highlighted its progress and future potential in treating periodontitis, proposing an evaluation model for its medical use.", "population_specificity": "Patients with periodontitis (clinical dental treatment context).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:15.620955+00:00"}
{"study_id": 26383, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 70, "quality_score": 40, "study_goal": "The researchers aimed to investigate the efficacy of molecular hydrogen therapy in a patient with SLE-PAH and decompensated right-sided heart failure.", "results_summary": "Molecular hydrogen therapy stabilized clinical symptoms, increased Tr1 cells, and decreased Treg cell subsets, B cell subsets, marginal cells, and plasma cells, with no adverse effects observed.", "population_specificity": "A 51-year-old female with SLE-PAH and decompensated right-sided heart failure precipitated by sepsis.", "effective_dosage": "Daily hydrogen capsules (specific dosage not provided).", "study_duration": "Not specified (intervention began in March 2024, abstract does not state end date).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:19.566407+00:00"}
{"study_id": 26382, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to evaluate whether molecular hydrogen therapy could serve as a beneficial adjunct treatment for subdural hematoma (SDH) with midline shift, particularly in modulating immune responses.", "results_summary": "The study found that hydrogen therapy appeared to enhance immune markers, specifically Treg and plasma cells, without adverse effects, suggesting potential benefits as an adjunct to conventional SDH treatments. However, recovery was primarily attributed to standard interventions.", "population_specificity": "A 24-year-old man with SDH, right-sided midline shift, uncal herniation, and dilated left pupil.", "effective_dosage": "Daily hydrogen capsules (specific dosage not mentioned).", "study_duration": "Began immediately upon admission (specific duration not mentioned).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:19.952830+00:00"}
{"study_id": 26384, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to evaluate the therapeutic impact of molecular hydrogen therapy on fatigue, immune modulation, and cardiac function in a patient with SLE and cardiac complications.", "results_summary": "Molecular hydrogen therapy, when used as an adjuvant, improved cardiac function, reduced fatigue, and modulated immune responses, as evidenced by favorable changes in antibody levels and T/B cell subsets. The patient successfully tapered off steroids while maintaining disease stability.", "population_specificity": "A 51-year-old female with systemic lupus erythematosus (SLE) and acute decompensated heart failure.", "effective_dosage": "Not specified", "study_duration": "Several months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:20.081321+00:00"}
{"study_id": 26385, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether molecular hydrogen-enriched dialysis (E-HD) alleviates dialysis-related fatigue and its association with metabolic profiles in hemodialysis patients.", "results_summary": "E-HD significantly reduced fatigue in patients with activity reduction (Group A), improved body composition (reduced fat, increased muscle mass in subgroup A2), and mitigated metabolic pathway differences between fatigued and non-fatigued groups. No significant changes were observed in Groups B and C.", "population_specificity": "81 hemodialysis patients classified by fatigue severity (Group A: fatigue with activity reduction, Group B: fatigue without activity reduction, Group C: no fatigue).", "effective_dosage": "Not specified", "study_duration": "12 months", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:21.047276+00:00"}
{"study_id": 26386, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to review the therapeutic benefits and potential applications of molecular hydrogen (H2) in treating oxidative stress-related diseases.", "results_summary": "Molecular hydrogen exhibits selective antioxidant properties, anti-inflammatory effects, and therapeutic benefits for various diseases, including cardiovascular, respiratory, metabolic, and neurological disorders. Administration methods include inhalation, hydrogen-rich water, and saline, with no reported adverse effects.", "population_specificity": "Not specified (review of experimental and clinical studies).", "effective_dosage": "Not specified (multiple administration methods mentioned).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:21.370566+00:00"}
{"study_id": 26387, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether molecular hydrogen (H2) administration could alleviate cognitive and immunological disturbances in a mouse model of vascular dementia (VaD).", "results_summary": "H2 treatment reversed anxiety-deficient behavior and memory impairment in VaD mice, mitigated neuronal damage and oxidative stress, restored BCL2 and IL-4 expression, and normalized T regulatory cell homeostasis. Transcriptomic evaluations confirmed H2's role in restoring neuroprotective and anti-inflammatory gene expression.", "population_specificity": "Adult male C57BL/6 mice with induced vascular dementia.", "effective_dosage": "Not specified (hydrogen-rich water treatment).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:22.376247+00:00"}
{"study_id": 26388, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential benefits of molecular hydrogen (H2) in mitigating oxidative stress and its superiority over conventional antioxidants.", "results_summary": "The study found that molecular hydrogen selectively reduces harmful hydroxyl radicals while preserving beneficial reactive oxygen species (ROS) used for cell signaling, offering advantages over traditional antioxidants in alleviating oxidative stress-related damage.", "population_specificity": "Not specified (general oxidative stress-related conditions).", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:22.572781+00:00"}
{"study_id": 26389, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the role of molecular hydrogen (H2) as an adjunct therapy to improve the effectiveness of mesenchymal stem cell (MSC) therapy by enhancing survival, growth, and therapeutic outcomes.", "results_summary": "The study found that molecular hydrogen exhibits strong antioxidative and anti-inflammatory effects, promoting MSC survival and function by quenching reactive oxygen species and stimulating the Nrf2 pathway. Combined with cold atmospheric plasma (CAP), H2 creates a favorable environment for MSCs, reducing healing time in wound repair, neuroprotection, and ischemia.", "population_specificity": "Mesenchymal stem cells (MSCs) in regenerative medicine contexts (e.g., wound healing, neuroprotection, ischemia).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:24.900156+00:00"}
{"study_id": 26391, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 45, "study_goal": "The researchers aimed to investigate the efficacy of adjunctive hydrogen therapy in improving renal function and reducing chronic fatigue in an elderly patient with multiple chronic comorbidities.", "results_summary": "Hydrogen therapy was associated with improved renal function (reduced serum creatinine levels) and significant alleviation of chronic fatigue in the patient. Immunological changes suggested potential immune modulation as a mechanism for the observed benefits.", "population_specificity": "An 89-year-old female with coronary artery disease, type 2 diabetes mellitus with nephropathy, and systemic lupus erythematosus.", "effective_dosage": "Not specified", "study_duration": "Not specified (initiated in January 2023, follow-up duration unclear)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:29.016331+00:00"}
{"study_id": 26392, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to calculate accurate Rayleigh and Raman scattering cross sections and related parameters for molecular hydrogen (H2) and generate Raman spectra using these data.", "results_summary": "The study calculated 9582 Rayleigh and Raman scattering cross sections for H2, presenting the most accurate and complete treatment of Raman scattering for molecular hydrogen to date. The results were compared with existing literature, and convergence with increasing intermediate electronic states was demonstrated.", "population_specificity": "Not applicable (theoretical/computational study)", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:29.212657+00:00"}
{"study_id": 26396, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the anti-inflammatory and antioxidant effects of oral solid hydrogen capsules (OSHCs) on individuals with chronic inflammation.", "results_summary": "OSHCs demonstrated prolonged oxidative reduction potential and regulated hydrogen release, leading to significant reductions in ESR, CRP, and DAS28 scores, along with improvements in fatigue and diabetes control measures.", "population_specificity": "Stable outpatients with chronic illnesses.", "effective_dosage": "Low-, medium-, and high-dose groups (specific amounts not detailed).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:30.240347+00:00"}
{"study_id": 26393, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether molecular hydrogen could regulate neuroinflammation and improve depressive-like behavior and cognitive impairment in senescence-accelerated mice.", "results_summary": "HRJ intake reduced depressive-like behavior, improved cognitive function, suppressed markers of oxidative stress and neuroinflammation, and lowered IL-6 levels in SAMP8 mice.", "population_specificity": "Senescence-accelerated mouse-prone 8 (SAMP8) and senescence-accelerated mouse-resistant 1 (SAMR1) mice.", "effective_dosage": "Not specified", "study_duration": "26-28 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:30.385892+00:00"}
{"study_id": 26394, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 75, "quality_score": 40, "study_goal": "The researchers aimed to evaluate the potential benefits of molecular hydrogen therapy in managing aneurysmal subarachnoid hemorrhage (SAH) in a patient with underlying autoimmune diseases.", "results_summary": "Daily treatment with hydrogen capsules resulted in increased Treg and Breg cells, elevated TIM3+ expression on Tc cells, and conversion of anti-dsDNA from positive to negative, stabilizing clinical symptoms without adverse effects.", "population_specificity": "A 44-year-old female with aneurysmal SAH, rheumatoid arthritis (RA), and newly diagnosed systemic lupus erythematosus (SLE), complicated by acute ischemic infarction.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:30.386444+00:00"}
{"study_id": 26390, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether molecular hydrogen could prevent and alleviate chronic itch in various conditions (dermatitis-induced, diabetic, and cholestatic itch) by reducing oxidative damage via SIRT1-dependent \u03b2-catenin deacetylation.", "results_summary": "Molecular hydrogen (via inhalation or injection) effectively reduced chronic itch, oxidative damage, and spinal pruriceptive sensitization by upregulating SIRT1 and antioxidant enzymes while decreasing ROS generation and dendritic spine density. SIRT1 inhibition negated hydrogen's antipruritic effects, while SIRT1 agonism replicated them.", "population_specificity": "Mice with persistent dermatitis, diabetes, or cholestasis.", "effective_dosage": "Hydrogen gas (2% inhalation) and hydrogen-rich saline (5 mL/kg, intraperitoneal injection).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:30.916448+00:00"}
{"study_id": 26395, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to investigate the efficacy and safety of molecular hydrogen therapy as an adjuvant treatment for connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).", "results_summary": "Molecular hydrogen therapy stabilized clinical symptoms, increased CD127+ Treg cells, reduced anti-Ro antibodies, and decreased B cell subsets in a patient with CTD-PAH unresponsive to conventional treatments, with no reported adverse effects.", "population_specificity": "A 56-year-old female with CTD-PAH, diagnosed with Sjogren's syndrome complicated by interstitial lung disease (ILD) and PAH.", "effective_dosage": "Daily hydrogen capsules (specific dosage not mentioned).", "study_duration": "Initiated in May 2023 (exact duration not specified).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:31.175200+00:00"}
{"study_id": 26397, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to investigate the therapeutic potential of molecular hydrogen (H2) in reducing inflammation and oxidative stress in extracorporeal circulation (ECC) settings, specifically in ECMO circuits.", "results_summary": "The study found that molecular hydrogen reduced biomarker concentrations associated with inflammation and oxidative stress in an LPS-treated ECMO circuit, suggesting potential anti-inflammatory and antioxidative effects. However, the influence of LPS was significant, and further research is needed to optimize H2 administration protocols.", "population_specificity": "Healthy adult donors (n = 7) in an in vitro ECMO circuit model.", "effective_dosage": "Not specified (H2 gas mixture used, but exact concentration not detailed).", "study_duration": "6 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:34.061417+00:00"}
{"study_id": 26400, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine if molecular hydrogen could serve as a pharmacological intervention to reduce opioid-seeking reinstatement and explore its mechanism via gut microbiota.", "results_summary": "Molecular hydrogen enhanced morphine-related behavior extinction, reduced reinstatement, improved gut microbial features, and alleviated depression and anxiety symptoms in opioid-addicted individuals.", "population_specificity": "Animal models (mice) and opioid-addicted humans.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:37.443442+00:00"}
{"study_id": 26399, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 30, "quality_score": 80, "study_goal": "The researchers aimed to determine if hydrogen-rich water (HRW) could reduce the risk of COVID-19 progression in patients with mild-to-moderate symptoms.", "results_summary": "HRW was not superior to placebo in preventing clinical worsening at day 14 (46.1% vs. 43.5%). Adverse events were similar between groups (27% vs. 26.2%), and mortality was slightly lower in the placebo group.", "population_specificity": "Primary care patients with mild-to-moderate, laboratory-confirmed COVID-19.", "effective_dosage": "Twice daily for 21 days (exact amount not specified).", "study_duration": "21 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:37.815038+00:00"}
{"study_id": 26403, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate whether molecular hydrogen (H2) can reduce the side effects of anticancer drugs and enhance their anticancer activity.", "results_summary": "The study found that H2 reduces oxidative stress and inflammation, protecting against tissue injuries caused by several anticancer drugs. It also suggests H2 may have its own anticancer properties, potentially enhancing the efficacy of existing treatments.", "population_specificity": "Not specified (abstract mentions animal studies and clinical trials but does not detail human or animal populations).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:40.198535+00:00"}
{"study_id": 26404, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether co-administration of cobalt protoporphyrin IX (CoPP) and hydrogen-rich water (HRW) could effectively treat paclitaxel (PTX)-induced neuropathy and associated emotional disorders in mice.", "results_summary": "The study found that combining CoPP and HRW produced faster and stronger antiallodynic effects than either treatment alone, reduced anxiodepressive-like behaviors, and modulated oxidative stress and inflammation in the amygdala and dorsal root ganglia. The combination also enhanced antioxidant system activation and reduced inflammatory markers.", "population_specificity": "Male C57BL/6 mice injected with paclitaxel (PTX).", "effective_dosage": "Low doses (specific amounts not provided).", "study_duration": "Not specified in the abstract.", "interactions": "Positive interaction noted between CoPP and HRW in enhancing therapeutic effects.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:43.662384+00:00"}
{"study_id": 26405, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to determine whether Molecular Hydrogen (H2) could promote physiological angiogenesis, suppress neovascularization, and protect glial cells in Retinopathy of Prematurity (ROP) using oxygen-induced retinopathy (OIR) mice.", "results_summary": "H2 (3-4%) improved vaso-obliteration and neovascularization in OIR mice, protected retinal astrocytes, reduced microglial activation, and promoted vascular regeneration via Nrf2 activation and suppression of the Dll4/Notch pathway. It also enhanced HUVEC proliferation under hypoxia by reducing ROS levels.", "population_specificity": "Seven-day-old wild-type and Nrf2-deficient mice with oxygen-induced retinopathy (OIR), and human umbilical vein endothelial cells (HUVECs) under hypoxia.", "effective_dosage": "3-4% hydrogen gas (H2) inhalation.", "study_duration": "Not explicitly stated (intervention administered at different stages post-OIR induction).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:44.851750+00:00"}
{"study_id": 26406, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of molecular hydrogen (H2) in treating chronic kidney disease (CKD) by examining its effects on oxidative stress and redox signaling pathways.", "results_summary": "Molecular hydrogen demonstrated promising therapeutic effects by scavenging harmful reactive oxygen species (ROS), activating the NRF2-KEAP1 pathway, modulating NF-\u03baB and HIF signaling, and enhancing antioxidant enzyme activity, though clinical trials remain limited.", "population_specificity": "Focused on chronic kidney disease (CKD) models, with implications for renal diseases broadly.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:45.446290+00:00"}
{"study_id": 26408, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 40, "study_goal": "The researchers aimed to evaluate the effectiveness of hydrogen-assisted therapy in managing progressive fibrosing interstitial lung disease (PF-ILD) complicated by pneumonia.", "results_summary": "The study observed noticeable improvement in lung infiltrations and a shift in immune phenotypes, including increased regulatory T cells and decreased Fas+ helper and cytotoxic T cells after hydrogen treatment.", "population_specificity": "An 85-year-old female with suspected IgG4-related PF-ILD and hospital-acquired pneumonia.", "effective_dosage": "Not specified", "study_duration": "4 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:47.983842+00:00"}
{"study_id": 26402, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to demonstrate the potential of molecular hydrogen as a \"smart medicine\" for treating Parkinson's disease by inhibiting dopamine oxidation and improving symptoms.", "results_summary": "The study suggests that molecular hydrogen can penetrate the brain, neutralize harmful hydroxyl radicals, and improve Parkinson's symptoms like body bending and hand tremor. A case of hydrogen inhalation showed symptom improvement, though broader clinical validation is implied but not detailed.", "population_specificity": "Parkinson's disease patients (specific sample size not provided).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:48.644032+00:00"}
{"study_id": 26401, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to investigate the role of molecular hydrogen (H\u2082) in mitigating oxidative stress and inflammation, particularly in the context of cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2DM).", "results_summary": "The study found that molecular hydrogen, whether produced endogenously in the gut or administered exogenously (via inhalation or H\u2082-rich water), exhibits potent anti-inflammatory and antioxidant effects, reducing oxidative stress and inflammation linked to CVDs and metabolic diseases. Clinical and experimental evidence supports its therapeutic potential, though larger studies are needed for confirmation.", "population_specificity": "General population, with a focus on individuals at risk for CVDs and T2DM.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:49.950793+00:00"}
{"study_id": 26409, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential benefits of priming mesenchymal stem cells (MSCs) with molecular hydrogen (H2) for regenerative medicine.", "results_summary": "The abstract suggests that molecular hydrogen priming of MSCs may enhance their therapeutic potential, though specific outcomes or results are not detailed. The approach is described as promising for regenerative medicine applications.", "population_specificity": "Not specified (abstract focuses on mesenchymal stem cells in general).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:51.516743+00:00"}
{"study_id": 26410, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to explore the effects of molecular hydrogen (H2) on retinal degeneration in rd1 mice, a model for inherited retinitis pigmentosa (RP).", "results_summary": "The study found no significant differences in retinal degeneration indicators (ERG, OCT, ONL thickness, Iba1-positive cells) between control and H2 intervention groups, suggesting H2 had no obvious effect on the disease course in rd1 mice.", "population_specificity": "rd1 mice (animal model of inherited retinitis pigmentosa)", "effective_dosage": "Not specified (three modes: two hydrogen gas and one hydrogen-rich saline)", "study_duration": "Intervention administered until P21 (21 days post born)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:53.669597+00:00"}
{"study_id": 26411, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to quantitatively assess the influence of Molecular Hydrogen (H2) on exercise-induced oxidative stress and antioxidant potential capacity in healthy adults.", "results_summary": "The study found that H2 supplementation did not significantly reduce exercise-induced oxidative stress but improved antioxidant potential capacity, particularly in intermittent exercise. Subgroup analyses indicated greater benefits for intermittent exercise compared to continuous exercise.", "population_specificity": "Healthy adults", "effective_dosage": "Various forms (hydrogen-rich water, hydrogen bathing, hydrogen-rich gas) with different timing (before, during, after exercise, or repeated over days). Specific dosages not detailed.", "study_duration": "Varied (single-dose, multi-dose within 1 day, or multiple-dose over days). Exact duration not specified.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:55.281366+00:00"}
{"study_id": 26412, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to review the therapeutic potential of molecular hydrogen (H2) in cancer treatment, its immunomodulatory effects, and the role of H2 produced by intestinal flora in immune homeostasis.", "results_summary": "The study found that H2 has therapeutic effects on various cancers, mitigates oxidative stress from radiation and chemotherapy, and enhances T cell anti-tumor function. H2 selectively scavenges toxic reactive oxygen species (ROS) and inhibits ROS-dependent signaling pathways in cancer cells.", "population_specificity": "Not specified (review of existing studies).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:56.680404+00:00"}
{"study_id": 26413, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether molecular hydrogen could improve gut microbiota dysbiosis and intestinal injury in high-fat diet-fed aging mice.", "results_summary": "Molecular hydrogen treatment improved markers of intestinal injury (CDX2, BrdU, MDA) and altered gut microbiota composition by increasing beneficial bacteria (Lactinobactor) and reducing harmful bacteria (Akkermansia, Gracilibacter, Marvinbryantia).", "population_specificity": "Senescence-accelerated mice (SAMP8) fed a high-fat diet.", "effective_dosage": "Not specified (administered as hydrogen-rich jelly).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:57.356175+00:00"}
{"study_id": 26407, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of combined inhaled nitric oxide (iNO) and molecular hydrogen (iH2) in patients with respiratory manifestations of post-COVID-19 syndrome (PS).", "results_summary": "The study found that combined iNO/iH2 significantly reduced symptoms like dyspnea, cough, fatigue, and palpitations, improved quality of life (SF-36 scores), reduced fatigue (FAS score), and enhanced physical performance (6-minute walk test). It also improved oxidative stress markers and microcirculation parameters.", "population_specificity": "34 patients (11 men, 23 women, mean age 60.0\u00b111.7 years) with post-COVID-19 syndrome.", "effective_dosage": "iNO at 60 ppm and iH2 at <4% concentration, inhaled for 90 minutes once daily.", "study_duration": "10 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:58.697165+00:00"}
{"study_id": 26415, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the current findings on hydrogen therapy's potential as a new drug substance, including its administration methods and clinical indications.", "results_summary": "Positive indications for hydrogen therapy were found in major disease areas such as cardiovascular diseases, cancer, and respiratory diseases, though challenges like explosive hazards and low solubility were noted. The study reviewed 81 clinical trials and 64 scientific publications, highlighting diverse ongoing research.", "population_specificity": "Human studies and clinical trials across various disease areas.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:59.237741+00:00"}
{"study_id": 26414, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 90, "quality_score": 80, "study_goal": "The researchers aimed to determine whether an antioxidant auxiliary system (AAS) supplying molecular hydrogen (H2) could alleviate cellular stress and enhance viral vaccine production in high-density cell cultures.", "results_summary": "The AAS maintained stable H2 concentration in media, reduced oxidative stress, and increased virus yields by 3.7-fold in bovine epidemic fever virus (BEFV) and 2.5-fold in porcine circovirus type 2 (PCV-2) cultures. H2 treatment was shown to be safe and effective in these models.", "population_specificity": "High-density cell cultures (bovine and porcine virus models).", "effective_dosage": "Not specified (delivered via proton exchange membrane electrolysis).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:46:59.711637+00:00"}
{"study_id": 26416, "supplement_id": 1347, "safety_score": "90", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to review the therapeutic effects of molecular hydrogen (H2) on ophthalmic diseases, including its administration approaches and underlying mechanisms.", "results_summary": "The study found that H2 alleviates oxidative damage, reduces inflammation, and inhibits apoptosis, showing protective effects in ophthalmic diseases like cataracts, dry eye disease, and diabetic retinopathy. Clinical applications for dry eye disease and corneal endothelial injury were noted, though further large-scale studies are needed for optimal dosage and application.", "population_specificity": "Patients with ophthalmic diseases (e.g., cataracts, dry eye disease, diabetic retinopathy).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:02.383686+00:00"}
{"study_id": 26418, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential therapeutic benefits of Molecular Hydrogen (H2) for diabetic kidney disease (DKD) by reviewing preclinical and clinical evidence.", "results_summary": "The study found that H2 exhibits antioxidant, anti-inflammatory, and mitochondrial function-enhancing properties, suggesting potential benefits for DKD patients. However, large-scale clinical trials are needed to substantiate these findings.", "population_specificity": "Patients with diabetic kidney disease (DKD) and animal models of renal diseases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:04.540544+00:00"}
{"study_id": 26417, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the role of molecular hydrogen in stroke management, including its antioxidative, anti-inflammatory, and antiapoptotic effects, and evaluate its safety and efficacy across different administration methods.", "results_summary": "The study found that molecular hydrogen demonstrated favorable outcomes in stroke management, with antioxidative, anti-inflammatory, and antiapoptotic effects. Preclinical and clinical studies supported its potential as a promising treatment option, though further optimization of dosage and administration routes is needed.", "population_specificity": "Patients with ischemic stroke (preclinical and clinical studies reviewed).", "effective_dosage": "Various formats (inhalation of hydrogen gas, intravenous or intraperitoneal injection of hydrogen-enriched solution, drinking hydrogen-enriched water) \u2013 specific dosages not detailed.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:04.613387+00:00"}
{"study_id": 26419, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the antitumor, antioxidant, anti-inflammatory, and antiapoptotic effects of molecular hydrogen (H2) in the treatment of glioblastoma (GBM).", "results_summary": "H2 inhalation suppressed GBM tumor growth in mice, extended survival, and reduced glioma cell sphere-forming, migration, invasion, and colony-forming abilities. Proton therapy was also noted to have advantages in treating central nervous system malignancies.", "population_specificity": "Mice with glioblastoma (GBM) and glioma cells in experimental studies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:06.222241+00:00"}
{"study_id": 26420, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to determine the effects of hydrogen-rich water (HRW) on coenzyme Q10 (CoQ10) levels and platelet mitochondrial bioenergetics in patients with non-alcoholic fatty liver disease (NAFLD).", "results_summary": "HRW supplementation increased platelet CoQ10 levels, reduced oxidative stress (TBARS), and improved mitochondrial OXPHOS efficiency in NAFLD patients, while placebo group changes were non-significant.", "population_specificity": "30 patients with NAFLD and 15 healthy volunteers.", "effective_dosage": "Three 330 mL doses per day of hydrogen-rich water (>4 mg/L H2).", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:07.566111+00:00"}
{"study_id": 26421, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 55, "study_goal": "The researchers aimed to determine whether 12-week intake of molecular hydrogen affects brain levels of neurotransmitters involved in appetite regulation in overweight adults.", "results_summary": "The study found significant decreases in glutamate, glutamate-plus-glutamine, GABA, and glutathione levels in specific brain regions, suggesting a possible hydrogen-driven upregulation of neurotransmitters linked to hunger suppression. No changes were observed in the untreated control group.", "population_specificity": "Overweight adults (5 treated, 4 controls; age range ~41-50 years, BMI ~26.8-29.4 kg/m\u00b2).", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:07.617849+00:00"}
{"study_id": 26422, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to identify target biomarkers for Molecular Hydrogen (H2) at the protein and genome levels, focusing on its protective, causal relationship with sepsis.", "results_summary": "The study identified Apoa2 as a target biomarker for H2, demonstrating a protective, causal relationship with sepsis. HDL and type 2 diabetes were also found to have causal relationships with sepsis, and modulation of Apoa2 influenced sepsis and related syndromes.", "population_specificity": "Mouse models (sepsis and normal).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:07.814154+00:00"}
{"study_id": 26423, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the protective effect of molecular hydrogen (H2) on kidney function in pigs undergoing cardiac surgery, specifically examining its impact on oxidative stress biomarkers and the Nrf2/Keap1 pathway.", "results_summary": "H2 therapy normalized elevated plasma biomarkers (creatinine, urea, phosphorus) and activated the Nrf2/Keap1 pathway, increasing SOD1 protein expression, suggesting a protective effect on kidneys post-cardiac surgery.", "population_specificity": "Pigs undergoing simulated heart transplantation with extracorporeal circulation.", "effective_dosage": "4% H2 mixed with air during anesthesia inhalation and blood oxygenation in ECC.", "study_duration": "Administered during surgery (3 hours) and 60 minutes of reperfusion.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:11.878864+00:00"}
{"study_id": 26426, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to analyze trends in medical research on molecular hydrogen, including its therapeutic applications and emerging research directions.", "results_summary": "The study found an upward trend in publications on molecular hydrogen therapy from 2007 to 2020, with oxidative stress and inflammation being the primary research focuses. Emerging hotspots included gut microbiota, pyroptosis, and COVID-19.", "population_specificity": "Not specified (analysis of published literature)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:13.411335+00:00"}
{"study_id": 26427, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effectiveness of molecular hydrogen in enhancing collagen fibrillogenesis and accelerating wound healing in second-degree burn wounds.", "results_summary": "Molecular hydrogen stimulated skin regeneration by activating collagen fiber formation and reducing damaged skin area, with effects comparable to a therapeutic ointment. The remodeling of the extracellular matrix correlated with improved wound healing, likely due to enhanced mast cell activity.", "population_specificity": "Subjects with second-degree burn wounds.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:14.982237+00:00"}
{"study_id": 26424, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of dairy industry side streams (whey) for cultivating microorganisms to produce molecular hydrogen (H2) and assess hydrogenase enzyme activity.", "results_summary": "The study demonstrated Hyd-3-dependent H2 production by E. coli using whey as a growth substrate, achieving prolonged H2 yields of ~5 mmol/L and cumulative H2 ~94 mL g/L dry whey. Enhanced biomass and H2 production were observed in a genetically modified E. coli strain, confirming whey as a viable substrate for biocatalyst production.", "population_specificity": "Escherichia coli BW25113 and Ralstonia eutropha H16 type strains (microbial cultures).", "effective_dosage": "Not specified (cultivation conditions: 37\u00b0C, pH 7.5 for E. coli; 30\u00b0C, pH 7.0 for R. eutropha).", "study_duration": "Not specified (monitored until stationary growth phase).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:15.309033+00:00"}
{"study_id": 26428, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine the effects of high-concentration molecular hydrogen (H2) on wound healing, specifically its role in extracellular matrix (ECM) deposition and epidermal stem cell (EpSCs) activation.", "results_summary": "High-concentration H2 (66%) significantly accelerated wound healing (3 times faster than control), promoted early ECM deposition, activated EpSCs proliferation and differentiation, enhanced vascularization, and reduced inflammation. The effects were independent of oxygen or anti-reactive oxygen species functions.", "population_specificity": "Cutaneous aseptic wound model (animal or in vitro study, exact species not specified).", "effective_dosage": "66% H2 in a treatment chamber (frequency not specified).", "study_duration": "Evaluated up to 11 days post-wounding.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:17.006804+00:00"}
{"study_id": 26429, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of H2 inhalation on the functional states of red blood cells (RBCs) in rats with chronic heart failure (CHF), focusing on oxidative stress markers and oxygen transport function.", "results_summary": "H2 inhalation increased erythrocyte electrophoretic mobility, reduced aggregation, and modulated lipid peroxidation, with more pronounced effects after multiple exposures. The findings suggest H2 improves microcirculation and oxygen transport, potentially benefiting CHF treatment.", "population_specificity": "Rats with chronic heart failure (CHF).", "effective_dosage": "Not specified (single and multiple H2 applications mentioned).", "study_duration": "Not specified (single and multiple exposures mentioned).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:17.284485+00:00"}
{"study_id": 26425, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the therapeutic role of molecular hydrogen (H2) in treating neurological diseases and its potential in promoting healthful longevity through redox mechanisms.", "results_summary": "The study found that molecular hydrogen acts as an antioxidant and anti-inflammatory agent, reducing oxidative stress and benefiting age-related diseases such as Alzheimer's, Parkinson's, cancer, and osteoporosis. It also promotes healthy aging by improving gut microbiota and reducing oxidative damage.", "population_specificity": "Not specified (general focus on age-related diseases and neurological conditions).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:21.133305+00:00"}
{"study_id": 26430, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic effects of hydrogen-rich water (HRW) on preventing bone loss in a zebrafish model of prednisolone-induced osteoporosis.", "results_summary": "HRW prevented osteoclast activation and bone loss in prednisolone-treated zebrafish scales but did not counteract osteoblast suppression or facilitate the repair of resorption lacunae. The study suggests HRW has a specific preventive effect on osteoclast activity but not on osteoblast function.", "population_specificity": "Zebrafish scales (model for secondary osteoporosis)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:21.776746+00:00"}
{"study_id": 26433, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the therapeutic potential of molecular hydrogen (H2) as an adjunctive or independent therapy for cancer treatment, focusing on its mechanisms and effectiveness.", "results_summary": "The study found that H2 therapy demonstrated consistent anti-proliferative, anti-oxidative, pro-apoptotic, and anti-tumoural effects across various cancer types, improving survivability, quality of life, blood parameters, and tumour reduction. However, more comprehensive research is needed to confirm these findings.", "population_specificity": "Cancer patients (specific types not detailed in the abstract).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:24.162779+00:00"}
{"study_id": 26432, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers sought to determine whether molecular hydrogen could mitigate brain damage and anxiety-like behavior induced by nuclear electromagnetic pulse (NEMP) exposure in rats.", "results_summary": "Molecular hydrogen alleviated NEMP-induced anxiety-like behavior and neuronal damage in the hippocampus and amygdala, with transcriptomic and metabolomic analyses suggesting its protective role via pathways like glutathione metabolism and neuroactive ligand-receptor interactions.", "population_specificity": "Male wild-type rats exposed to NEMP.", "effective_dosage": "Saturated hydrogen-rich water (specific concentration not stated), administered from 3 days pre-exposure until sacrifice.", "study_duration": "Intervention began 3 days before NEMP exposure and continued until sacrifice (1 or 7 days post-exposure).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:24.365296+00:00"}
{"study_id": 26434, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the therapeutic potential of molecular hydrogen in neurological diseases by examining its antioxidative and anti-inflammatory effects.", "results_summary": "Molecular hydrogen demonstrated neuroprotective effects in stroke, neurodegenerative diseases, neurotrauma, and global brain injury by selectively scavenging pathological free radicals and influencing cellular pathways. The therapy showed promise in animal studies and some clinical trials.", "population_specificity": "Neurological disease models (stroke, neurodegenerative diseases, neurotrauma, global brain injury) in animals and humans.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:25.309623+00:00"}
{"study_id": 26437, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the therapeutic potential of molecular hydrogen (H2) in alleviating mental disorders induced by methamphetamine (METH) abuse, focusing on its effects on gut microbiota and neuropsychiatric symptoms.", "results_summary": "Hydrogen intervention (drinking and inhalation) significantly alleviated mental disorders in METH abusers and altered gut microbiota profiles, particularly restoring hydrogen-producing bacteria like Bacteroides and Roseburia. The study suggests H2 has potential therapeutic benefits for METH-induced neuropsychiatric conditions.", "population_specificity": "METH abusers, with specific focus on female users showing altered gut microbiota.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:30.548236+00:00"}
{"study_id": 26436, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether Molecular Hydrogen (H2) could improve cognitive dysfunction and reduce tau phosphorylation in a mouse model of sepsis-associated encephalopathy (SAE).", "results_summary": "H2 inhalation improved survival rates, cognitive function, and dendritic spine density in septic mice while reducing phosphorylated tau protein, tau oligomers, and TTBK1 levels, suggesting a protective role against SAE.", "population_specificity": "C57BL/6J male mice with sepsis induced by cecal ligation and puncture surgery.", "effective_dosage": "2% H2 inhalation for 60 minutes at 1 hour and 6 hours post-surgery.", "study_duration": "Acute intervention (single day) with outcomes assessed up to 7 days post-surgery.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:30.686585+00:00"}
{"study_id": 26431, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to systematically assess the effects of molecular hydrogen (H2) supplementation on fatigue and aerobic capacity in healthy adults.", "results_summary": "The meta-analysis found that H2 supplementation had a small but significant effect on reducing perceived exertion (RPE) and blood lactate levels, indicating alleviation of fatigue, but it did not significantly improve aerobic capacity (VO2max, VO2peak) or endurance performance. Subgroup analysis showed that the effects on fatigue varied based on training status, intervention period, and exercise type.", "population_specificity": "Healthy adults", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:32.999810+00:00"}
{"study_id": 26439, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to investigate the hydrogen-generating abilities of silicon particles synthesized by centrifugal chemical vapor deposition (cCVD) for potential in vivo hydrogen administration.", "results_summary": "The study found that cCVD silicon particles produced high hydrogen generation rates (up to 1310 ml/g at pH 7.4) and remained effective after pretreatment in artificial gastric juice, suggesting suitability for in vivo use. However, surface carbon coatings, surfactants, albumin, or egg white reduced hydrogen generation.", "population_specificity": "Not specified (in vitro model).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:33.249688+00:00"}
{"study_id": 26438, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the effects of molecular hydrogen on gut microbiota changes and metabolic regulation in sepsis-associated encephalopathy (SAE) in mice.", "results_summary": "Molecular hydrogen treatment improved functional outcomes in SAE, reduced inflammation in the brain and gut, and partially corrected gut microbiota dysbiosis and metabolic disorders.", "population_specificity": "Male wild-type mice with sepsis-associated encephalopathy (SAE).", "effective_dosage": "2% hydrogen gas inhalation and hydrogen-rich water (specific frequency not mentioned).", "study_duration": "24 hours after model establishment (intervention duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:33.518619+00:00"}
{"study_id": 26440, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to determine the effects of molecular hydrogen (H2) inhalation on erythrocyte metabolism and oxidative stress markers in patients with chronic heart failure.", "results_summary": "Inhalation of 2% H2 increased ATP and 2,3-DPG levels, reduced malondialdehyde concentration, and enhanced catalase activity, indicating improved erythrocyte metabolism and reduced oxidative stress. Repeated H2 exposure showed more pronounced effects than a single session.", "population_specificity": "Patients with chronic heart failure.", "effective_dosage": "2% molecular hydrogen inhalation for 40 minutes, either once or repeatedly over 5 days.", "study_duration": "5 days (repeated exposure) or a single 40-minute session.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:35.987265+00:00"}
{"study_id": 26443, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 78, "quality_score": 82, "study_goal": "The researchers aimed to assess the neuroprotective effects of molecular hydrogen following ischemic brain injury and its potential as a therapeutic agent for neurodegenerative diseases.", "results_summary": "The study found that molecular hydrogen has pleiotropic neuroprotective properties, improving cognitive and neurological deficits, and preventing or delaying neurodegenerative changes post-ischemia. It also suggests potential benefits in preventing aging-related protein changes like amyloid and tau dysfunction.", "population_specificity": "Animal models of focal or global cerebral ischemia and humans with cerebral ischemia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:39.047314+00:00"}
{"study_id": 26442, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine the role of molecular hydrogen (H2) in enhancing the survival and myogenic differentiation of adipose-derived stem cells (ADSCs) in an oxidative stress-rich microenvironment.", "results_summary": "An appropriate volume fraction of H2 reduced mitochondrial reactive oxygen species (ROS), increased mitochondrial number, promoted mitophagy, and improved ADSC survival and myogenic differentiation.", "population_specificity": "Adipose-derived stem cells (ADSCs) in vitro.", "effective_dosage": "Not specified (referred to as \"an appropriate volume fraction\").", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:39.197158+00:00"}
{"study_id": 26441, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to investigate the potential role of molecular hydrogen as a component of anesthesia in surgical treatment with cardiopulmonary bypass (CPB) and its effects on red blood cell function and cardiac activity.", "results_summary": "Molecular hydrogen inhalation improved red blood cell function, reduced oxidative stress, and enhanced myocardial contractile function post-surgery compared to the control group. The study found statistically significant differences in these outcomes between the research and control groups.", "population_specificity": "24 patients undergoing elective surgery with CPB for acquired valve defects at a specialized cardiosurgical hospital in Russia.", "effective_dosage": "1.5-2.0% H2 via facemask during anesthesia and throughout the operation.", "study_duration": "Duration of the surgical procedure (exact time not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:39.487181+00:00"}
{"study_id": 26445, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine how thermal treatment during the synthesis of N-doped ZnO affects its photocatalytic efficiency, particularly in water photosplitting reactions.", "results_summary": "The study found that low-temperature treatments produced N-doped ZnO with higher efficiency in water photosplitting, making it more effective for artificial photosynthesis. The thermal treatment was crucial in selecting specific molecular defects, influencing the material's chemical reactivity (reduction vs. oxidation).", "population_specificity": "Not applicable (material science study, no human or animal subjects).", "effective_dosage": "Not applicable", "study_duration": "Not applicable", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:41.193257+00:00"}
{"study_id": 26446, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to assess the potential therapeutic effect of molecular hydrogen (H2) on colorectal cancer (CRC) by examining its impact on cell proliferation, apoptosis, and tumor growth via the pAKT/SCD1 pathway.", "results_summary": "Hydrogen treatment suppressed CRC cell proliferation and reduced tumor volume and weight in vivo by inhibiting the pAKT/SCD1 pathway. SCD1 expression was higher in CRC tissues and correlated with advanced disease stages and poorer outcomes.", "population_specificity": "Colorectal cancer cell lines (RKO, SW480, HCT116) and xenograft mouse models; 491 human CRC tissue specimens.", "effective_dosage": "Inhalation of 67% hydrogen for two hours per day (in vivo).", "study_duration": "Not specified (abstract does not mention duration beyond daily dosing).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:43.148108+00:00"}
{"study_id": 26447, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to review the potential of molecular hydrogen (H2) in ameliorating mitochondrial dysfunction and fatigue, particularly in ME/CFS, based on existing animal and clinical studies.", "results_summary": "The literature review suggested that H2 may improve acute and chronic fatigue by attenuating mitochondrial dysfunction, though further clinical trials are needed to confirm efficacy and mechanisms in ME/CFS.", "population_specificity": "Animals, healthy people, and implied relevance to ME/CFS patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:45.543910+00:00"}
{"study_id": 26435, "supplement_id": 1347, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to review the therapeutic potential, administration routes, mechanisms, and challenges of molecular hydrogen in treating various brain disorders.", "results_summary": "Molecular hydrogen demonstrated antioxidative and anti-inflammatory effects, showing therapeutic potential for neurodegenerative disorders and brain injuries, though optimal dosage and molecular targets require further study.", "population_specificity": "Patients with brain disorders (e.g., Alzheimer's, Parkinson's, stroke, traumatic brain injury).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:45.581052+00:00"}
{"study_id": 26448, "supplement_id": 1347, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the therapeutic and preventive effects of molecular hydrogen on ageing and ageing-related diseases.", "results_summary": "Molecular hydrogen exhibits antioxidative properties, reduces oxidative stress, and may mitigate cellular senescence, inflammation, and ageing-related processes. It shows potential for preventing and treating various ageing-related diseases, including neurodegenerative disorders, cardiovascular disease, and cancer.", "population_specificity": "Not specified (general ageing-related mechanisms and diseases).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T21:47:46.488267+00:00"}
